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EXECUTIVE SUMMARY 
 
1 INTRODUCTION 
1.1 Aims of the review 
To review the effectiveness of harm reduction approaches with the intention of quitting (ie 
‘cutting down to quit’ or ‘reduction to stop smoking’), with and without assistance. 
 
 
1.2 Research questions 
 How effective are pharmacotherapies in helping people cut down smoking before 
quitting? 
 How effective are different combinations of nicotine replacement therapy (NRT) 
products in helping people cut down smoking before quitting? 
 How effective are ‘nicotine-containing products’ in helping people cut down smoking 
before quitting? 
 How effective are behavioural support, counselling, advice or self-help (with or 
without pharmacotherapy) in helping people cut down smoking before quitting? 
 Is there an optimal period for helping people cut down smoking with the aim of 
quitting? 
 Is it more or less effective to draw up a schedule to help someone cut down smoking 
with the aim of quitting? 
 Do some tobacco harm-reduction approaches have a differential impact on different 
groups (for example, people of different ages, gender, socioeconomic status or 
ethnicity)? 
 Are there any unintended consequences from adopting a tobacco harm-reduction 
approach, for example, does it deter people from trying to stop smoking? 
 
 
1.3 Background 
Although smoking rates have declined sharply in the last 30 years, this decline has slowed in 
recent years. In the past, public health strategies with respect to smoking have focused on 
discouraging people from starting to smoke and helping smokers to quit the habit completely. 
There remains a group of smokers who either want to quit but feel unable to stop abruptly or 
otherwise are not willing or able to quit but may be prepared to reduce the amount they 
smoke. The healthiest course of action for all smokers is to stop smoking but harm reduction 
measures attempt to limit the risks by reducing exposure to the toxic chemicals found in 
tobacco smoke (Royal College of Physicians, 2007). NICE has been asked by the Department of 
Health to develop guidance on ‘Tobacco – harm reduction approaches to smoking’. Building on 
the review of safety, risk and pharmacokinetics of tobacco harm reduction (THR) technologies 
(Jones et al, 2011), this review is the first of two effectiveness reviews to support the guidance 
development.  A second effectiveness review on long term smoking reduction without the 
intention of quitting and a companion review of barriers and facilitators to harm-reduction 
approaches will follow. The series will be completed with a health economic analysis of THR 
approaches.   
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2  METHODS 
 A systematic review of effectiveness evidence to address the above review question has been 
undertaken. A wide range of databases and websites was searched systematically, supplemented by 
grey literature1 searches. Searches were carried out in August 2011 to identify relevant studies in the 
English language published between 1990 and 2011. All populations of all ages were included other 
than pregnant women, with a particular focus on those who have been identified as being more likely 
to smoke, at increased health risk from smoking and/or experiencing health inequalities.   
Interventions considered were: 
 Pharmacotherapies that are licensed for cutting down, temporary abstinence or harm 
reduction (currently only  nicotine replacement therapy is licensed for these indications),  
 Other non-tobacco nicotine containing products (e-cigarettes and topical gels) 
 behavioural support, counselling, advice or self help   
All smoking-related outcomes were considered. 
Study selection and quality assessment were conducted independently in duplicate, with inter-rater 
reliability testing and monitoring. Data was extracted by one reviewer and checked by a second.   
A narrative summary of the evidence was completed along with a meta-analysis of findings where 
feasible. 
 
3. RESULTS 
A total of 14 papers (12 studies) have been included in the review. See Table 1 (pp. 22-23) for a brief 
summary of the studies. Full details are provided in the Evidence Tables (Appendix A).  
The quality was generally of a moderate standard in terms of study design and clarity of reporting. Five 
studies are randomised controlled trials (Etter 2009 +, Etter 2011 +, Gunther 1992–, Hughes 2010 ++, 
Shiffman 2009 ++), four are quasi-randomised (Cinciripini 1994 +, Cinciripini 1995 +, Martin 1997 +, 
Marks 2002 +2). The remaining three papers are a partial randomised trial (O’Leary Tevyaw 2007 –), 
uncontrolled before and after studies (Jiménez-Ruiz 2009 –, Riley 2002 –) and a secondary analysis of 
Hughes 2010 (Hughes 2011 –). Only one UK study was identified (Marks 2002 +). Three were 
conducted in Europe (Etter 2009 +, Jiménez-Ruiz 2009– and Gunther 1992–), six in the USA (Cinciripini 
1994 +, Cinciripini 1995 +, Hughes 2010 ++, Martin 1997 +, Riley 2002 –, Shiffman 2009 ++) and one 
was a web-based intervention that was open to users of a smoking cessation website regardless of 
location (Etter 2011 +). 
Nine studies took place in community settings, two of which were in community based smokers' clinics 
(Jiménez-Ruiz 2009 –, Marks 2002 +). Etter 2011 + was a web-based intervention; O’Leary Tevyaw 
2007– and Riley 2002 – were conducted in high schools.  
 
                                                          
1
 Technical or research reports, doctoral dissertations, conference papers and official publications.   
2
 There are two papers reporting one study: Marks 2002 (reporting 12 month data) and Sykes 2001 (reporting six month data 
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4. EVIDENCE STATEMENTS 
Q1. How effective are pharmacotherapies in helping people cut down smoking before quitting? 
Three RCTs examined the efficacy of NRT gum (Etter 2009 +, Shiffman 2009 ++) and lozenges 
(Hughes 2010 ++). In addition there was one quasi-randomised controlled trial (Martin 1997 +) 
and one uncontrolled before and after study (Jiménez-Ruiz 2009 –) with a combined 
intervention of behavioural therapy plus gum. 
Both Shiffman 2009 ++ and Hughes 2010 ++ were deemed to be studies at low risk of bias.  
Evidence Statements:  
1.1  There is moderate evidence from two randomised controlled trials (RCTs) of no 
significant difference in long-term abstinence rates between gradual and abrupt 
cessation when using NRT (gum or lozenges) (Etter 2009 +, Hughes 2010 ++) 
although the trend favours abrupt cessation. The CO and cotinine validated four 
week quit rate at 12 months was 16.5% for gradual compared to 24.0% for abrupt 
cessation, p=0.14 (Etter 2009 +), The OR for CO validated abstinence at 6 months 
(gradual/abrupt) was 0.6 (95% CI 0.3, 1.2) (Hughes 2010 ++).   
1.2 There is moderate evidence from a large RCT (Shiffman 2009 ++) of a benefit from 
NRT versus placebo at  6 months; this was more marked in the 4 mg gum versus 2 
mg dose rates with ORs of 6.0 (95%CI 2.9,  12.3)  and 1.8 (95% CI 1.1,  2.9) 
respectively.  Overall OR 2.86 (95% CI 1.93, 4.24). 
  Evidence from two much smaller studies, a quasi-RCT (Martin 1997 +) and an 
uncontrolled before and after study (Jiménez Ruiz 2009  –), is inconsistent. In the 
quasi–RCT mean quit rates for standard treatment versus  behavioural counselling 
with  NRT respectively at  6months were 21% v. 27% (NS)  and at 12 months 26% v 
27% (NS) (Martin 1997 +). In the UCBA study (Jiménez Ruiz 2009 –) 39% reported 
abstinence at 6 months and 68% reported ≥50% reduction in cigarette 
consumption at the end of 8 weeks using a combination of gum and behavioural 
therapy. The difference in abstinence between participants who wanted to reduce 
to quit versus those who were refractory smokers was not significant (48% vs 32%, 
p=0.8).   
1.3 There is inconsistent evidence from one RCT (Etter 2009 +) and one UBA (Jiménez 
Ruiz 2009 –) of NRT use in the longer term.  Etter 2009 + found that, after 12 
months, 9.2% participants were still using NRT daily (5 pieces per day on average).  
Values were similar in both abrupt and gradual cessation groups.  Jiménez Ruiz 
2009 – found that all smokers who had successfully quit at 16 weeks continued to 
use NRT into the abstinence phase but no subject used NRT for more than 4 
months post quit date. 
 
1.4   There is weak evidence from a single RCT that nicotine gum may be an effective aid 
to reducing cigarettes prior to cessation as daily cigarette consumption in the week 
before the quit date was  12.4 v 21.3 cigarettes /day, p<0.001 (Etter 2009 +). 
The evidence from the RCTs (Etter 2009 +, Hughes 2010 ++, Shiffman 2009 ++) is partially 
applicable to people in the UK because, although there were no UK-based trials, the 
studies were community-based and are feasible within a UK setting. Martin 1997 + relates 
specifically to recovering alcoholics.  Jiménez Ruiz 2009 – was an intensive intervention 
which is unlikely to be feasible within the UK. 
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Q2. How effective are different combinations of NRT products in helping people cut down smoking 
before quitting? 
Evidence Statement:  
2.1  No studies were found that looked at combinations of NRT products for helping people to 
cut down before quitting.  
 
 
Q3. How effective are ‘nicotine-containing products’ in helping people cut down smoking before 
quitting? 
For the purposes of this review ‘nicotine containing products’ were defined as ‘electronic 
nicotine delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-cigarettes’) and 
topical gels. 
Evidence Statement:  
3.1   No studies were found that looked at the effectiveness of nicotine delivery systems 
(electronic cigarettes) for helping people to cut down before quitting. 
 
 
Q4. How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people cut down smoking before quitting? 
 
Nine studies incorporated behavioural support, including three randomised controlled trials 
(Etter 2011 +, Gunther 1992 −, Hughes 2010 ++), four quasi-randomised controlled trials 
(Cinciripini 1994 +, Cinciripini 1995 +, Martin 1997 +, Marks 2002 +), one trial with partial 
randomisation (O’Leary Tevyaw 2007 –) and two uncontrolled before and after studies 
(Jiménez-Ruiz 2009 –, Riley 2002 – ).  
Studies used behavioural intervention components in a variety of ways:  
 Cognitive behavioural support (Cinciripini 1994 +, Marks 2002 +) 
 Advice giving (Etter 2011 +) 
 Investigating the feasibility of contingency management3 (O’Leary Tevyaw 2007 –) 
 Investigating the feasibility of computerised scheduled reduction (Riley 2002 –). 
In the other studies, all participants received a behavioural component (Cinciripini 1995 +, 
Gunther 1992 –, Hughes 2010 ++, Jiménez-Ruiz 2009 –, Martin 1997 +) and it is therefore not 
possible to infer the effectiveness of that component. 
Evidence Statements:  
4.1  There is moderate evidence for the effectiveness of cognitive behavioural therapy 
versus standard therapy from two quasi-RCTs (Cinciripini 1994 +, Marks 2002 +) 
both in reducing the number of cigarettes per day prior to quitting, and in quitting 
itself. At 12 months 41% of the CBT group and 6% of the control group were 
                                                          
3
  O’Leary Tevyaw describes contingency management as promoting “decreases in substance use by providing tangible reinforcers 
contingent on abstinence or reduction of substance use to a target level”. The ‘tangible reinforcers’ in this study are gift 
certificates for use in a local shopping centre. 
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abstinent, p<0.01. Figures for 6 months were 53% and 6%, p<0.01 (Cinciripini 1994 
+). At 12 months 19.8% (95% CI 13.0, 28.3) of the contactable CBT group were 
abstinent compared to 5.8 % (95% CI 2.1, 12.1, p<0.0001) (Marks 2002 +). At the 
same time point 11.5% (95% CI 6.4, 18.5, p<0.0001) had reduced their CPD by ≥ 
25% compared to 0% in the control group. 
4.2 There is moderate evidence from two RCTs (Gunther 1992 –, Hughes 2010 ++) of a 
trend towards higher abstinent rates for abrupt cessation compared to gradual 
reduction when counselling is offered to both groups (with nicotine as well in 
Hughes 2010 ++) but the findings are not significant. The OR for CO verified 
abstinence at 6 months for gradual versus abrupt cessation was 0.6 (95% CI 0.3, 
1.2) (Hughes 2010 ++). At 12 months follow-up there was a non-significant 
difference in self reported abstinence between sudden and gradual withdrawal 
groups: 51.85% versus 38.71% (Gunther 1992 –). 
4.3  There is weak evidence from one quasi-randomised trial (Cinciripini 1995 +) 
suggesting that cognitive behavioural therapy combined with advice to schedule 
and lengthen the time between cigarettes may enhance outcomes. Cotinine 
verified abstinence rates at 12 months were 44% (scheduled reduced), 18% (non-
scheduled reduced), 32% (scheduled non-reduced) and 13% (non-scheduled non-
reduced); p<0.05.   
4.4 There is weak evidence from one RCT (Etter 2011 +) to suggest that there may be 
no difference in the effect of advice giving (via web and email) for gradual versus 
abrupt cessation but the follow up period was very short and outcomes were self 
reported. At four weeks 8.8% of the gradual group and 8.7% of the abrupt group 
reported no puff taken in the past 24 hours (p=0.97). 
4.5 There is weak evidence from one RCT (Martin 1997 +) in a population of recovering 
alcoholics that there may be no difference between standard treatment with 
counselling, counselling plus exercise and counselling plus NRT for gradual 
reduction. CO-verified quit rates at 12 months for the three groups were26%, 27% 
and 27% respectively. 
4.6 There is very weak evidence from a feasibility study (O’Leary Tevyaw 2007 –) 
suggesting that the use of contingency management (a reward for response) may 
be effective when used to support reduction to quit since participants had more 
abstinent readings in the contingency management phase than the reinforcement 
phase (50% vs 37%).   
4.7 There is very weak evidence from two small before & after studies (Riley 2002 –) 
that computerised scheduled reduction, with or without behavioural support, is 
acceptable to a teenage population. 
This evidence is partially applicable to people in the UK. The use of rewards for response 
(O’Leary Tevyaw 2007 –) is unlikely in this setting. However Marks 2002 + was based in 
the UK, Etter 2011 + was a web-based intervention and all the other studies were 
community- or high school-based and feasible within a UK setting. 
 
 
 
Q5. Is there an optimal period for helping people cut down smoking with the aim of quitting 
Among the included studies, the reduction period varied from 7-10 days (Marks 2002 +) through 
to 16 weeks (Jiménez-Ruiz 2009 –).  Five studies employed reduction periods of between two 
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and five weeks (Cinciripini 1994 +, Cinciripini 1995 +, Etter 2009 +, Etter 2011 +, Hughes 2010 
++). Riley 2002 – utilised a seven-week and Martin 1997 + and Shiffman 2009 ++ an eight-week 
schedule.   
Martin 1997 + found no difference between two different reduction periods, although the 
interventions also differed. CO-verified quit rates at 12 months for the three groups (standard 
treatment with counselling over 4 weeks, counselling plus exercise and counselling plus NRT 
over 8 weeks) were 26%, 27% and 27% respectively. 
None of the other included studies compared the effectiveness of different periods of cutting 
down prior to quitting. There was considerable variation in design between the studies and it is 
not possible to identify any relationship or trend between the length of the reduction period 
and the outcomes that is not subject to potential confounding by other aspects of the study 
designs. 
However, Hughes 2011 – carried out a secondary analysis to examine whether delaying a quit 
attempt was associated with less success. This analysis was considered to be at high risk of bias. 
Evidence Statement:  
5.1 There is weak evidence from a secondary analysis (Hughes 2011 –) and a quasi-RCT  
(Martin 1997 +) to indicate that there is no relationship between time to planned or actual 
quit date and long term abstinence rate among those cutting down prior to quitting.  
5.2 There is no evidence concerning the optimum cuttjng-down period from other studies 
(Cinciripini 1994 +, Cinciripini 1995 +, Etter 2009 +, Etter 2011 +, Hughes 2010 ++, 
Jiménez-Ruiz 2009 –, Marks 2002 +, Riley 2002 –, Shiffman 2009 ++). Reduction periods 
varied from 7 days to 16 weeks. None of the studies explored the effect of the reduction 
time on outcomes and, given the huge heterogeneity between studies, no relationship 
between reduction time and outcomes can be inferred.  
This evidence is partially applicable to people in the UK who smoke because Hughes 2011 – was 
a large community based study that may be feasible in the UK, although a secondary analysis is a 
methodologically weak study.  Martin 1997 + looked specifically at recovering alcoholics. 
 
 
 
Q6. Is it more or less effective to draw up a schedule to help someone cut down smoking with the 
aim of quitting? 
One quasi-RCT compared scheduled versus non-scheduled reduction (Cinciripini 1995).  One RCT 
(Hughes 2010++) and one quasi-RCT (Martin 1997 +) compared different types of schedule.   
Evidence Statements:  
6.1 There is weak evidence from one quasi-RCT for scheduled versus non-scheduled 
reduction. Cinciripini 1995 + found that cognitive behavioural therapy combined 
with advice to schedule and lengthen the time between cigarettes enhanced 
outcomes.  Cotinine-verified abstinence rates at 12 months: 44% (scheduled 
reduced), 18% (non-scheduled reduced), 32% (scheduled non-reduced) and 22% 
(non-scheduled non-reduced); p<0.05.  
6.2 There is weak evidence from one large RCT (Hughes 2010 ++) and one quasi-RCT 
(Martin 1997 +) that the type of smoking reduction schedule used does not make a 
difference.  Hughes 2010 ++) reported that reduction and abstinence rates did not 
appear to differ across the initially chosen methods (formal schedule, giving up 
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‘easiest’ cigarettes first, giving up ‘hardest’ cigarettes first) so the results were 
pooled across all the methods. Martin 1997 + found no difference between 
different intervention and scheduled reduction methods. CO-verified quit rates at 
12 months for the three groups (standard treatment with counselling over 4 weeks, 
counselling plus exercise and counselling plus NRT over 8 weeks) were 26%, 27% 
and 27% respectively. 
This evidence is partially applicable to people in the UK since the studies are community 
based and feasible in UK settings. One study (Martin 1997 +) however was in a specific 
population (recovering alcoholics). 
 
 
 
Q7. Do some tobacco harm-reduction approaches have a differential impact on different groups 
(for example, people of different ages, gender, socioeconomic status or ethnicity)? 
Only two studies, both RCTs, examined differences across groups. Etter 2011 + compared 
findings according to age and sex, whilst Marks 2002 + examined differences according to 
gender and socio-economic group. Neither study found evidence of a difference between the 
groups. 
Evidence Statements:  
7.1 There is moderate evidence from two RCTs (Etter 2011 +, Marks 2002 +) to suggest that 
tobacco harm reduction approaches do not appear to have a differential impact on 
abstinence rates (Etter 2011 +, Marks 2002 +) or CPD (Marks 2002 +) according to age, 
gender (Etter 2011 +, Marks 2002 +) or socioeconomic group (Marks 2002 +).  
This evidence is applicable to people in the UK since Marks 2002 + was based in the UK and Etter 
2011 + was web-based and is feasible in a UK setting. 
 
 
Q8. Are there any unintended consequences from adopting a tobacco harm-reduction approach, 
for example, does it deter people from trying to stop smoking? 
Three RCTs (Cinciripini 1995 +, Etter 2009 +, Hughes 2010 ++) and a secondary analysis (Hughes 
2011 –) provided evidence on various unintended consequences. 
Evidence Statements:  
8.1 There is moderate evidence from one large well conducted RCT (Hughes 2010 ++) to 
suggest that gradual reduction may be associated with a decreased likelihood of making a 
quit attempt, and that delaying the quit attempt may lead to an increased risk of relapse. 
However it should be noted that the overall difference in 6-month quit rate from abrupt 
versus gradual NRT-aided cessation was not statistically significant (see statement 1.1).  
For every week’s delay to quit date the probability of lapsing increased by 19%. In a 
secondary analysis of this RCT (Hughes 2011 –) 57% of the gradual group had either quit 
after their planned date or did not make a quit attempt at all, which was somewhat higher 
than those in the abrupt (29%) and control (33%) groups, although this relationship was 
not tested statistically.   
8.2 There is weak evidence from one RCT (Etter 2009 +) suggesting there is no increased risk 
of long term use when NRT is first used as an aid to reduction compared to when it is used 
simply as an aid to abrupt cessation. After 12 months 9.2% of participants were using 
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nicotine gum daily and values were similar in both groups. 
8.3 There is weak evidence from one RCT (Cinciripini 1995 +) that people cutting down to quit 
using a scheduled reduced approach experience fewer withdrawal symptoms in quit and 
post-quit weeks and less tension in the quit week compared to the other reduction 
approaches tested (no data provided). 
This evidence partially applicable to people in the UK since the studies were community based 
and are feasible in UK settings. 
 
 
5. DISCUSSION 
This systematic review found few intervention studies that were designed to look specifically at cut 
down to quit interventions. Furthermore, those studies varied considerably in methodology, in the 
interventions used, the outcomes measured and the participant populations. 
The quality of the included studies was moderate at best. Only two studies were rated as having a low 
risk of bias (Hughes 2010 ++, Shiffman 2009 ++) and four were rated as being at high risk of bias 
(Gunther 1992 –, Jimenez-Ruiz 2009  –, O’Leary Tevyaw 2007 –, Riley 2002 –); as was a secondary 
analysis of the Hughes 2010 ++ data (Hughes 2011 –).  
There was a wide variation in the range of outcomes; both in timeframes (four weeks to twelve 
months) and assessment methods (self-reported, CO or cotinine verified). 
Participant motivation was sometimes difficult to ascertain and few studies were conducted in 
participants who wanted to quit but did not want to do so abruptly. For this reason, the scope of the 
review was extended to include all individuals who participated in a cut down to quit study. 
Only one study was conducted in the UK (Marks 2002 +), and it is difficult to assess how applicable the 
other studies are likely to be although it seems reasonable to assume web- and community-based 
programmes in the USA and Europe are feasible within a UK setting. Some interventions had 
significant resource implications (12 hours counselling for Gunther 1992 –, eight clinic visits for 
Jiménez-Ruiz 2009–, incentive payments for O’Leary Tevyaw 2007 –, and/or very specific populations 
(recovering alcoholics in Martin 1997 +, US high school students in O'Leary Tevyaw 2007 – and Riley 
2002 –). 
Overall, the data suggest that it is reasonable to give those who are looking to give up smoking the 
choice of whether they cut down gradually or quit abruptly. Also to provide choice over the method of 
reduction (scheduled, over a short or long time period). However, these conclusions need to be set 
against the findings from Hughes 2010 ++. This study suggests a reduction approach may allow 
smokers to delay their quit attempts and increase the likelihood of relapse. There are indications that 
NRT support may enhance the ability of smokers to quit abruptly over purely behavioural approaches.  
Although some study samples were from disadvantaged groups there was very little evidence on 
differential impact between groups 
Further research is clearly needed: more high quality studies that are adequately powered with 
consistent outcome measures to help answer the questions of what techniques work best and for 
whom (both in terms of participant motivation and particular population groups). 
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ABBREVIATIONS  
 
ALA American Lung Association 
BEX Behavioural counselling plus exercise 
BNIC Behavioural counselling plus nicotine replacement therapy 
C  Control group 
CM  Contingency management  
CO  Carbon monoxide 
CPD  Cigarettes per day 
DH  Department of Health 
DSM Diagnostic and Statistical Manual of Mental Disorders 
GEE Generalised estimating equation 
GP   General Practitioner 
HR-E  Hierarchical reduction – easiest first 
HR –H  Hierarchical reduction – hardest first 
I  Intervention group 
ITT Intention to treat  
MANOVA Multiple analysis of variance 
MI Motivational interviewing 
NA Nicotine Anonymous 
NHS   National Health Service 
NICE  National Institute for Health and Clinical Excellence 
NM New Mexico 
NRT  Nicotine replacement therapy 
NS Not significant 
NTIS  National Technical Information Service 
OR   Odds ratio 
QFL Quit for Life 
RA Reinforcement for attendance 
RT Randomised trial (all intervention arms, no control) 
RCT  Randomised controlled trial 
SA Secondary analysis 
SC South Carolina 
SES Socio-economic status 
SSME Stop Smoking Made Easier 
SR Scheduled reduction 
ST  Standard treatment 
UBA Uncontrolled before and after study 
WHO World Health Organisation 
THR 2.3 Review 2 - Effectiveness of tobacco harm reduction approaches with the intention of quitting, with and without 
assistance 
 
 
13  
 
1 INTRODUCTION 
1.1 Aims of the review 
To review the effectiveness of harm reduction approaches with the intention of quitting (ie 
‘cutting down to quit’ or ‘reduction to stop smoking’), with and without assistance. 
 
1.2 Research questions 
 How effective are pharmacotherapies in helping people cut down smoking before 
quitting? 
 How effective are different combinations of NRT products in helping people cut down 
smoking before quitting? 
 How effective are ‘nicotine-containing products’ in helping people cut down smoking 
before quitting? 
 How effective are behavioural support, counselling, advice or self-help (with or 
without pharmacotherapy) in helping people cut down smoking before quitting? 
 Is there an optimal period for helping people cut down smoking with the aim of 
quitting? 
 Is it more or less effective to draw up a schedule to help someone cut down smoking 
with the aim of quitting? 
 Do some tobacco harm-reduction approaches have a differential impact on different 
groups (for example, people of different ages, gender, socioeconomic status or 
ethnicity)? 
 Are there any unintended consequences from adopting a tobacco harm-reduction 
approach, for example, does it deter people from trying to stop smoking? 
 
1.3 Background 
Although smoking rates have declined sharply in the last 30 years, this decline has slowed in 
recent years with prevalence rates levelling off at 21% in England in 2008 (Robinson and 
Bugler, 2010) and 24% in Wales in 2009 (Welsh Assembly Government, 2010). Fourteen 
percent of adults in managerial and professional households in England reported that they 
currently smoked, compared with 29% in routine and manual households; the corresponding 
figures for Wales were 15% versus 31%.   
People from routine and manual occupational groups take in more nicotine from cigarettes 
than more affluent people (Jarvis 2010). This increases their exposure to the other toxins in 
tobacco smoke and, thus, increases their risk of smoking-related disease. Higher nicotine 
exposure can also make it harder for them to quit and they are more likely to cut down first 
rather than quit smoking ‘abruptly’ (Siahpush et al. 2010). Exposure to increased levels of 
nicotine, carbon monoxide and other toxins can also result from 'roll-your-own' as compared 
to manufactured cigarettes (UK Department of Health Tobacco Policy Team 2003). 
In the past, public health strategies with respect to smoking have focused on discouraging 
people from starting to smoke and helping smokers to quit the habit completely. There 
remains a group of smokers who either want to quit but feel unable to stop abruptly or 
otherwise are not willing or able to quit but may be prepared to reduce the amount they 
smoke. The healthiest course of action for all smokers is to stop smoking but harm reduction 
measures attempt to limit the risks by reducing exposure to the toxic chemicals found in 
tobacco smoke (Royal College of Physicians, 2007). 
Harm reduction is defined as ‘policies, programmes, services and actions which aim to reduce 
the harm to individuals, communities and society that are associated with the use of drugs’. 
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Such measures are pragmatic, recognising that the reduction of harms may be more feasible 
than complete elimination of drug use (UK Harm Reduction Alliance).  
In relation to tobacco use specifically a product is considered harm reducing ‘if it lowers total 
tobacco-related mortality and morbidity, even though use of that product may involve 
continued exposure to tobacco related toxicants’ (Stratton et al, 2001).  Harm reduction can 
refer both to those who want to quit but feel unable to do so abruptly, and those who smoke 
and do not feel willing or able to quit but who want to reduce the harm that smoking is doing 
to their health, or to the health of those around them (Royal College of Physicians, 2007). 
Smokers continue to smoke predominantly due to nicotine addiction, but in so doing expose 
themselves to a large number of chemicals, many of which are established carcinogens. 
Tobacco smoke contains over 4,000 chemicals, including carbon monoxide, nitrosamines, 
polycyclic aromatic hydrocarbons, nitrogen oxides, hydrogen cyanide and heavy metals. 
Furthermore, exposure to second-hand smoke in the home causes an estimated 11,000 deaths 
a year in the UK from lung cancer, stroke and ischaemic heart disease (Jamrozik 2005).   
The Royal College of Physicians estimate that if only 0.4% of the population of smokers in the 
UK switch from smoking to less harmful nicotine sources each year, this would save 
approximately 25,000 lives in 10 years. In addition, the Department of Health’s (DH) 
publication ‘Drug Misuse and dependence: UK guidelines on clinical management’ states that: 
‘Given the high rates of smoking and the low quit rates in drug misusers, it may be reasonable 
to consider harm reduction approaches to smoking such as replacing cigarettes with clean 
nicotine in the form of patches for some of the day. This may be particularly useful in 
alleviating the symptoms of tobacco withdrawal while a patient is within a residential or 
inpatient drug treatment facility’ (DOH, 2007). 
A systematic review of the evidence (Pisinger 2007) found that the limited data available 
suggest that a substantial reduction in smoking (defined in many studies as ≥50% reduction in 
baseline smoking) improves several cardiovascular risk factors and respiratory symptoms. In 
addition, smoking reduction is associated with a 25% decline in biomarkers and incidence of 
lung cancer and a small, non significant, increase in birth weight. 
Although harm reduction strategies have been successful in other areas, when applied to 
tobacco they are controversial. For example there may be unintended consequences of 
adopting harm reduction measures such as ex-smokers relapsing to the harm reduction option 
and young people starting off with the harm reduction option in the belief that it is safer. In 
such cases it is possible the benefits may be overwhelmed by more widespread uptake of 
harm reduction measures. Another criticism levelled against harm reduction measures is that 
they represent an admission of defeat and still leave the smoker exposed to harm (Bates, 
2002). 
The National Institute for Health and Clinical Excellence (NICE) has been asked by the 
Department of Health to develop guidance on ‘Tobacco – harm reduction approaches to 
smoking’. This guidance will provide recommendations for good practice based on the best 
available evidence of effectiveness, including cost effectiveness. It is aimed at professionals, 
commissioners and managers with public health as part of their remit. It is especially aimed at 
those involved in smoking cessation services within the NHS, local authorities and the wider 
public, private, voluntary and community sectors. It will also be of interest to members of the 
public, especially people who want to stop or cut down the amount they smoke. 
The guidance will make recommendations on approaches to help smokers of all ages who: 
 want to quit smoking but feel unable to do so ‘abruptly’ (that is, they want to cut down 
before quitting) 
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 are not willing or able to quit, but want to reduce the harm that smoking is doing to 
their health (or to the health of those around them) 
 want to quit smoking but are not willing or able to stop using nicotine 
 want to stop smoking temporarily, for example, while at work.  
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2.  METHODS 
2.1 Literature search 
A comprehensive literature search was undertaken to identify evidence in the English language 
that is:  
 of the highest quality available, considering the hierarchy of evidence ; 
 applicable to the UK, from world-wide studies;   
 of high methodological quality, as assessed by critical appraisal;  
 publicly available, including trials in press (“academic in confidence”).  
The following study designs were included:   
 systematic reviews, guidelines, randomised controlled trials; controlled trials;  
[Systematic reviews and guidelines were identified and 'unpicked' for relevant studies 
to avoid any risk of double-counting.] 
 controlled before and after studies, interrupted time series and uncontrolled before 
and after studies were considered for potential relevance, especially where evidence 
from controlled trials was limited.  
The following study designs were excluded: 
 Surveys and other observational studies that were not designed to measure the 
efficacy of an intervention. Data from these types of study, where relevant to barriers 
and facilitators to tobacco harm reduction approaches, will be considered in Review 4. 
 
2.1.1 Electronic sources (databases and websites) 
The following sources were searched in August 2011 to identify relevant intervention 
studies in the English language published between 1990 and 2011.  
The search strategy was developed for Ovid Medline [Appendix C] and translated for 
use in all other sources detailed below.  A full set of search strategies are available 
from the authors. 
Databases: 
• AMED (Allied and Complementary Medicine) 
• ASSIA (Applied Social Science Index and Abstracts) 
• British Nursing Index 
• CINAHL (Cumulative Index of Nursing and Allied Health Literature) 
• Cochrane Central Register of Controlled Trials 
• Cochrane Database of Systematic Reviews 
• Cochrane Public Health Group Specialized Register [based at SURE] 
• Database of Abstracts of Reviews of Effectiveness (DARE) 
• Database of promoting health effectiveness reviews (DoPHER), EPPI-Centre 
• Current Contents 
• EMBASE 
• HMIC (or King’s Fund catalogue and DH data) 
• Medline and Medline in Process 
• UK Clinical Research Network Portfolio Database 
• PsycINFO 
• Sociological Abstracts 
• Social Policy and Practice 
• Web of Knowledge (Science and Social Science Citation Indexes) 
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• WHO Tobacco Control Database 
Web sites: 
• Smoke free http://smokefree.nhs.uk   
• NHS Centre for Smoking Cessation and Training http://www.ncsct.co.uk/   
• Action on Smoking and Health (ASH) http://www.ash.org.uk     
• Treat tobacco.net  http://www.treatobacco.net/en/index.php   
• Society for Research on Nicotine and Tobacco  http://www.srnt.org    
• International Union against Cancer  http://www.uicc.org  
• WHO Tobacco Free Initiative (TIF)  http://www.who.int/tobacco/en   
• International Tobacco Control Policy Evaluation Project  
http://www.itcproject.org   
• Tobacco Harm Reduction  http://www.tobaccoharmreduction.org/index.htm   
• Current controlled trials www.controlled-trials.com   
• Association for the treatment of tobacco use and dependence (ATTUD) 
www.attud.org   
• National Institute on drug abuse- the science of drug abuse and addiction  
http://www.nida.nih.gov/nidahome.html  
• NICE  http://www.nice.org.uk/  
• OpenGrey http://www.opengrey.eu/  
• Public health observatories http://www.apho.org.uk/  
• Scottish Government http://home.scotland.gov.uk/home  
• Welsh Government http://wales.gov.uk/?lang=en  
• NHS Evidence  http://www.evidence.nhs.uk/  
• Joseph Rowntree Foundation http://www.jrf.org.uk/  
• The Centre for Tobacco Control Research (University of Stirling) 
http://www.management.stir.ac.uk/research  
• UK Centre for Tobacco Control Studies 
http://www.ukctcs.org/ukctcs/index.aspx  
• Tobacco Control Research Group (University of Bath) 
http://www.bath.ac.uk/health/tobacco/   
• Health Evidence Canada http://health-evidence.ca/articles/search   
• ASH Scotland news digest http://www.ashscotland.org.uk/ash/4782    
• American Association of Public Health Physicians 
http://www.aaphp.org/tobacco  
• Health NZ News  http://www.healthnz.co.nz/News2010.htm  
• Globallink  http://www.globalink.org    
• Cancer Research UK http://www.cancerresearchuk.org  
 
2.1.2 Additional searches 
Following database and web site searching, the contents pages of the ‘top’ journals (ie 
the journals that contain the greatest number of papers that meet inclusion criteria) 
were hand searched - Drug & Alcohol Dependence (3 papers) and Nicotine & Tobacco 
Research (2 papers)] - for the previous twelve months.  Citation searches via Web of 
Science were also carried out for included papers. 
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NICE issued a call for evidence from registered stakeholders in August 2011. 
In addition, first authors of all the studies that met the inclusion criteria and other 
topic specialists identified by the Expert Advisory Group and NICE (Appendix A) were 
contacted to request information on additional published studies, unpublished work or 
research in progress.   
Information on studies in progress, unpublished research or research reported in the 
grey literature was sought through searching a range of relevant databases including 
OpenGrey, Conference Proceedings Citation Index: Science (Thompson Reuters), Inside 
Conferences, National Technical Information Service (NTIS) and Clinical Trials.gov 
Results of the literature searches were imported into Reference Manager and de-
duplicated. 
2.2   Inclusion and exclusion criteria: 
 Inclusion Exclusion 
Population People of all ages who want to quit 
smoking but feel unable to do so 
abruptly; or those who participate in cut 
down to quit interventions; with a 
particular focus on those who have been 
identified as:  
 to smoke,  
 at increased health risk from smoking, 
 from more disadvantaged groups and, 
thus, vulnerable to health 
inequalities.   
Pregnant women 
[but the post partum population 
was included] 
Interventions  Pharmacotherapies that are licensed 
for cutting down, temporary 
abstinence or harm reduction:  
o All nicotine replacement therapy 
(NRT) products (gum, transdermal 
patches, inhalers, microtabs, 
mouth/nasal sprays and lozenges4) 
 Other non-tobacco ‘nicotine-
containing products’, such as 
‘electronic nicotine delivery systems’ 
(sometimes known as ‘electronic 
cigarettes’ or ‘e-cigarettes’) and 
topical gels.  
 Behavioural support, counselling or 
advice for individuals/groups. 
 Self help. 
 
 Pharmacotherapies that are 
not licensed for cutting down, 
temporary abstinence or harm 
reduction; including nicotine 
agonists (eg varenicline) and 
antidepressants (eg 
bupropion).  
 Any products containing 
tobacco. This includes products 
that claim to deliver reduced 
levels of toxicity (such as 'low 
tar' cigarettes), or that reduce 
exposure to tobacco smoke, for 
example, by warming instead 
of burning it.  
 Products that are smoked that 
do not contain tobacco, such as 
herbal cigarettes.  
                                                          
4
 Nicotine replacement therapy preparations are licensed for adults and children over 12 years, with the exception of Nicotinell® 
lozenges which are licensed for children under 18 years only when recommended by a doctor (BNF accessed online 28 July 2011) 
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 Smokeless tobacco products 
such as gutka, or paan.  
 ‘Snus’ or similar oral snuff 
products as defined in the 
European Union’s Tobacco 
Product Directive (European 
Parliament and the Council of 
the European Union 2001).  
 Alternative or complementary 
therapies, such as 
hypnotherapy or acupuncture.  
Comparison All comparators  
Outcomes All types of outcomes (validated and 
unvalidated)  
 
 
Where interventions of interest were compared to/used in combination with excluded 
interventions, studies were included if the data for the interventions of interest could be 
disaggregated. Where disaggregation was not possible they were excluded. 
2.3 Study selection 
Titles and abstracts were screened independently by two reviewers using the inclusion/ 
exclusion parameters. Any disagreement was resolved by discussion with a third reviewer and, if 
in doubt, included. Full paper screening was also undertaken independently by two reviewers, 
with recourse to a third to resolve any disagreements. Inter-rater reliability testing produced a 
Kappa score of 0.79.  
During the screening process records were tagged for relevance to specific questions and 
populations of interest. Final inclusion was agreed by the review team. Excluded papers were 
retained with reasons for exclusion.  Papers of potential relevance to review teams undertaking 
associated reviews were identified and forwarded to those teams.  
2.4  Quality assessment  
Quality assessment was conducted independently in duplicate using the GATE checklist for 
quantitative studies [NICE 2009]. Any disagreement was resolved by discussion. The review 
team assessed each study’s internal and external validity; where external validity measured how 
far the findings of the study might be generalised beyond the participants to a wider population 
from which the participants were drawn (eg from one community setting in the US to all US 
communities) but not to other populations. These ratings are included in the evidence tables.  In 
addition, Appendix B provides a summary of the quality ratings for each element of the included 
studies that was assessed. Where randomisation methods were unclear or insufficient, the study 
is described as quasi-randomised. Inter-rater reliability scores were explored and resulted in an 
overall kappa score of 0.71. 
2.5  Applicability to the UK 
Based on advice from members of the Expert Advisory Group, it was agreed that research from 
settings where the smoking reduction and cessation programmes are sufficiently similar to those 
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in the UK (including Spain, Norway, Denmark, Australia and New Zealand) would be assessed as 
having high applicability to the UK. 
2.6  Data extraction 
Data were extracted as specified in Appendix K of the NICE Public Health Methods Manual and 
are presented in the Evidence Tables with study characteristics, quality scores and outcome 
measures reported by the authors are used (with associated 95% confidence intervals (CI) and p-
values where available). 
2.7 Data synthesis 
The key findings of evidence have been summarised in concise narrative summaries and 
evidence statements and are supported by evidence tables (Appendix A). The statements 
indicate:  
 the message given by the evidence; 
 the strength of the evidence (based on a quality assessment of the source studies); 
 the applicability of the results to the UK. 
Where feasible, meta-analyses of the data were conducted (see Appendix I).  
Dichotomous outcomes data are presented as relative risk ratios (RR) and, where possible, all 
outcomes data are provided with associated 95% confidence intervals (CI) and p-values.  
Clinical heterogeneity was assessed by examining the characteristics of the studies, the similarity 
between the types of participants, interventions, and comparisons. The degree of heterogeneity 
between the studies was assessed using the I² statistic. (Higgins 2011).   
 Following discussion between the review team and the Expert Advisory Group it was agreed 
that the included studies were highly clinically heterogeneous and the value of meta-analysis 
was very doubtful. Thus the results are not included in the Key Findings section 4. 
The strength of evidence assessment in the evidence statements is based on the most recent 
GRADE guidance (Guyatt 2010). The definitions used are broadly defined as follows with 
potential for moving up or down a grade as summarised in the guidance (Guyatt 2010): 
GRADE low, very low quality  = weak evidence (eg before and after studies graded –) 
GRADE moderate quality  = moderate evidence (eg RCTs/quasi RCTs graded +) 
GRADE high quality   = strong evidence (eg RCTs graded ++) 
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3.  RESULTS 
3.1 Search Results 
The search strategy identified 9750 citations of which 9271 were excluded at title and abstract. 
Of the remaining papers to be considered in full text, 17 were unavailable, 70 were found to be 
clearly irrelevant and 46 were systematic reviews. This left 346 papers which were considered 
for inclusion in one or more of the three reviews. 54 papers were considered for this review, of 
which 14 papers from 12 studies were included. A full list of excluded papers for this review with 
reasons for exclusion is provided in Appendix  
Note:
1) Some papers may be relevant to more than one review
2) New studies are likely to be identified whilst the reviews are being conducted
Databases 
Websites 
Unpicked reviews
9750
Full text 
479
Unavailable
17
Long term  
reduction
223
Clearly irrelevant
70
Systematic reviews 
(unpicked)
46
Barriers and 
Facilitators
118
This 
review
54
Full text 
346
Excluded
40
This 
review
14
Excluded 
Title and abstract 
9271
 
Note: 
1) Some papers may be relevant to more than one review 
2) New studies may be identified within update searches  for the long term reduction and barriers & 
facilitators reviews 
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A brief summary of each of the included studies is provided in Table 1.  
Of the 14 papers, five are randomised controlled trials (Etter 2009 +, Etter 2011 +, Gunther 1992 
–, Hughes 2010 ++, Shiffman 2009 ++), four are quasi-randomised (Cinciripini 1994 +, Cinciripini 
1995 +, Martin 1997 +, Marks 2002 +); receiving that designation because the allocation method 
was either unclear or inappropriate. The remaining five papers are a partial randomised trial 
(O’Leary Tevyaw 2007 –), uncontrolled before and after studies (Jiménez-Ruiz 2009 –, Riley 
2002 –), six month data for Marks 2002 (Sykes 2001 +) and secondary analysis of Hughes 2010 
(Hughes 2011 –).   
3.2 Quality and applicability of studies 
Only two of the RCTs were assessed as being of high quality and received a rating of ++ (Hughes 
2010, Shiffman 2009). Four studies were deemed to be at serious risk of bias and received a 
rating of – (Gunther 1992, Jiménez-Ruiz 2009, O’Leary Tevyaw 2007, Riley 2002 –)  as did the 
secondary analysis (Hughes 2011). The remaining studies all received a rating of + (Cinciripini 
1994, Cinciripini 1995, Etter 2009, Etter 2011, Martin 1997, Marks 2002) reflecting concerns 
about potential sources of bias. 
Only one of the studies included a power calculation (Etter 2011 +) and three were conducted in 
very small populations (Cinciripini 1994 +, O’Leary Tevyaw 2007 –, Riley 2002 –). Four of the 
studies which described themselves as randomised, provided no information on study allocation 
and are consequently described throughout as quasi-randomised (Cinciripini 1994 +, Cinciripini 
1995 +, Martin 1997 +, Marks 2002 +). Several studies had limited population data (Cinciripini 
1994 +, Cinciripini 1995 +, Gunther 1992 –). Two had no intention to treat analysis (Gunther 
1992–, Marks 2002 +).  
Both the studies that received a quality rating of ++ had lead authors with strong ties to 
manufacturers of smoking cessation products and Shiffman 2009 ++ was funded and co- 
authored by a pharmaceutical company. 
Study applicability is limited. Only one study was conducted in the UK (Marks 2002 +). Three 
were conducted in Europe (Etter 2009 +, Jiménez-Ruiz 2009 –, Gunther 1992 –), six in the USA 
(Cinciripini 1994 +, Cinciripini 1995 +, Hughes 2010 ++, Martin 1997 +, O’Leary Tevyaw −, Riley 
2002 –, Shiffman 2009 ++) and one was a web-based intervention that was open to users of a 
smoking cessation website regardless of location (Etter 2011 +). 
Nine studies took place in community settings; two of which were in smokers' clinics (Jiménez-
Ruiz 2009 –, Marks 2002 +). Of those not-community based, Etter 2011 + was a web based 
intervention and O’Leary Tevyaw 2007 – and Riley 2002 – were conducted in high schools. 
3.3 Outcomes 
Data were extracted for all smoking-related outcomes. Abstinence data (both sustained and 
point prevalence) were extracted for six and twelve months follow-ups, or the longest available 
period if these data were not available. Both self-report and verified abstinence (CO or cotinine) 
were extracted. In addition, information on reduction in smoking, number of cigarettes smoked 
per day (CPD) was identified. 
Whilst data concerning the impact of reducing smoking on mood was sought, particularly in 
relation to withdrawal symptoms, only one study (Cinciripini 1995 +) contained any relevant 
data. 
THR 2.3 Review 2 - Effectiveness of tobacco harm reduction approaches with the intention of quitting, with and without assistance 
 
23 |  
 
Table 1: Brief summary of included studies  
* Studies are complex and this table can only give a flavour of each intervention. See Appendix A for more detailed summaries. 
Author and 
Year  
Location and 
setting5  
Population 
 
Study outline Internal validity6 
Cinciripini 
1994 Quasi 
RCT 
USA  +  
(community-
based)   
34 adults 
Attrition: 6% 
Behavioural support for scheduled smoking reduction (over a three-week period) with 
a minimal self-help treatment. Control provided with an "I Quit Kit" advocating 
reduction to quit over a 7 day period.  C0-verified abstinence, CPD to 12 months.  
Participants' motivations unknown. 
+  Small sample), limited baseline data, no 
information on allocation, no power calc. 
Cinciripini 
1995 Quasi-
RCT 
USA +   
(community-
based)   
128 adults 
Attrition: not stated 
Behavioural support (CBT) for scheduled and non-scheduled reduction with scheduled 
and non scheduled abrupt cessation with meetings held up to 9 weeks. 
Cotinine verfied abstinence, CPD to 12 months. Tension to 6 months. 
Participants' motivations unknown. 
+  No information on allocation, little 
population detail, no power calc. 
Etter 2009 
 RCT 
Switzerland ++ 
(community-
based) 
314 adults 
Attrition: 11.8% 
NRT (nicotine polacrilex gum) 4 weeks before and 8 weeks after target quit date. 
Control had NRT for 8 weeks post quit date. 
Cotinine and CO verified abstinence, CPD to 12 months. 
Participants committed to a quit date. 
+  Pre-quit delay (2 weeks) may have 
introduced bias, no power calc.  
Etter 2011    
RCT 
Website + 
(multiple 
countries) 
974 adult internet 
users 
Attrition: 'high'   
Behavioural support via email.  Instruction via web/email to quit abruptly or gradually 
(via 2 week reduction period).Abstinence to 4 weeks 
Participants without preference for gradual/abrupt quitting 
+  ‘High’ drop-out rate reported by authors 
(no data provided), no biochemical 
verification of outcomes, short term 
follow up (4 weeks). 
Gunther 
1992    
RCT 
Austria + 
(community  
smokers’ centre) 
110 adults 
Attrition: 53% 
Behavioural support by 12 hours counselling for sudden versus gradual withdrawal. 
Abstinence and CPD to 12 months. 
 Participants' motivations unknown. 
 – No baseline data, significant loss to follow 
up, no biochemical verification of 
outcomes, no ITT, no power calc. 
Hughes 2010 
RCT 
USA  +  
(community-
based)   
746 adults 
Attrition: 21-24% 
but ITT 
Behavioural support by counselling and NRT for gradual reduction (cessation 3-5 
weeks after initiation) or abrupt cessation (1-3 weeks after initiation) 
CO verified abstinence and CO verified reduction, self efficacy, motivation, 
confidence, preference for quitting method to 6 months. 
Participants wanted to quit gradually. 
++  Team, though not this study, funded by 
pharma companies. No power calc and 
authors indicate study may be 
underpowered, but generally well 
conducted. 
                                                          
5
 The symbols (++ + –) in this column refer to the external validity; where ++ indicates an intervention that is applicable to all members of the population for which the study was designed. As external 
validity decreases, it is measured by + and then –. 
6
 The symbols in this column provide a summary rating for quality; where ++ indicates that the study has been conducted so as to minimise risk of bias. As quality decreases/risk of bias increases, it is 
measured by + and then –.  
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Hughes 2011  
Secondary 
analysis 
As above As above To explore the effect of delaying the quit attempt on outcomes. – Secondary analysis (and thus open to 
significant bias) 
Jiménez-Ruiz 
2009 
Uncontrolled 
B&A 
Spain –              
(Smokers’ Clinic) 
116 adults 
Attrition: 49% by 
week 16 
Cognitive behavioural support over 16 weeks with NRT for progressive reduction 
leading to abstinence.  No control group. 
CO verified abstinence up to 6 months. Reduction in CPD ≥50% at week 8. Adverse 
events. 
 Participants wanted to quit gradually. 
–   Uncontrolled study and potential bias in 
self-selected study sample. No power 
calc. 
Martin 1997  
Quasi-RCT 
 USA  +  
(community-
based)   
205 recovering 
alcoholics 
Attrition: not stated 
Standard treatment plus behavioural support for quitting (by week 4) versus 8 weeks 
behavioural counselling and exercise for reduction to quit vs behavioural counselling 
plus NRT for reduction to quit. 
CO verified abstinence up to 12 months.  
Participants' motivations unknown. 
+  Unclear whether appropriate allocation, 
no usual care control group, no power 
calc. 
Marks 2002  
Sykes 2001  
Quasi RCT 
UK ++         
(Smoking clinic in 
deprived London 
community) 
260 adults 
Attrition: 15% 
Cognitive behavioural support (an 'eclectic' mix) for a 7-10 day reduction period 
versus leaflet with staged preparation for abrupt cessation. 
CO verified abstinence and CPD reduction ≥ 25% up to 6 and 12 months. 
Participants' motivations unknown but all contacted a cessation clinic. 
+  Unclear allocation concealment. no ITT,  
no power calc. Authors are suppliers of 
the QFL (cognitive behavioural) 
intervention. 
O’Leary 
Tevyaw 2007 
Partial RCT 
USA –                       
(High school) 
23 adolescents 
Attrition: 7% 
Contingency management (by voucher payments) for reinforcement for reduction 
leading to abstinence versus reinforcement of abstinence only over a 3 week 
intervention. 
CO verified abstinence 2 weeks post intervention.   
Participants did not need to be motivated to quit. 
–  Very small sample (23) and short time-
frame for outcome measures (2 weeks 
post intervention). No power calc. 
Riley 2002 
Uncontrolled 
B&A 
USA –                       
(High school) 
17 (Study 1) and 18 
(Study 2) 
adolescents 
Attrition: 71% - 12 
month CO validated 
Two studies using computerised scheduled reduction combined with 7 weekly 
support meetings (study 1) or brief mid-point contact only (study 2). 
Self report CPD and 7-day abstinence, CO validated, at post-treatment (study 1 & 2), 
and 12 months (study 2 only). 
Participants had a desire to quit smoking. 
–  Very small samples (17/13), groups very 
different so can’t compare, high attrition 
for 12 month CO measure.  No power calc. 
Authors work for company with 
commercial interests in computerised 
smoking cessation products. 
Shiffman 
2009   RCT 
USA  +  
(community-
based)   
3297 adults 
Attrition: not stated 
NRT (2 mg or 4mg depending on participant choice) versus placebo for reduction to 
quit, over 8 weeks. 
CO verified abstinence up to 6 months, CPD, adverse events during reduction period 
(0-8 weeks). 
Participants were interested in quitting gradually. 
++  No data on attrition, pharma company 
funded and were involved in write up, no 
power calc. (though large study, n=3297) 
and generally well conducted. 
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4. FINDINGS 
Q1. How effective are pharmacotherapies in helping people cut down smoking before quitting? 
No studies provided cost-effectiveness data. 
Nicotine replacement therapy (NRT) products are the only pharmacotherapies with a UK 
marketing authorisation for cutting down, temporary abstinence or harm reduction.7 NRT is 
available in the following formulations: chewing gum, transdermal patches, inhalers, microtabs, 
mouth/nasal sprays and lozenges.  
RCTs comparing gradual versus abrupt cessation:  
Etter 2009 + gave intervention participants 4mg nicotine gum for four weeks before and eight 
weeks after the target quit date and told participants to decrease their cigarette consumption 
by 50% before quitting. Control group participants were recommended to quit abruptly and 
were given nicotine gum for eight weeks after the quit date only.  Participants were instructed 
to use ≥ 10 pieces of gum per day and received a booklet and a url for a cessation web site.  At 
the 12 month follow-up survey there was no statistically significant difference between the two 
groups in terms of biochemically validated four week quit rate (16.5% of the gradual group 
compared to 24% of the abrupt group p=0.14). After 12 months, 9.2% participants were still 
using NRT daily (5 pieces per day on average). Values were similar in both abrupt and gradual 
cessation groups.   
Hughes 2010 ++ carried out a three arm trial comparing nicotine lozenges combined with 
gradual cessation counselling, abrupt cessation counselling, and brief advice.  Participants in the 
gradual group were asked to set a quit date between three and five weeks after the study 
initiation and received nicotine lozenges for use; those in the abrupt and brief advice groups 
were asked to set a quit date between one and three weeks from the study onset. All 
participants were sent a booklet and nicotine lozenges to use starting on their quit date and for 
up to 12 weeks post quit date. The three conditions did not differ statistically in CO validated 
abstinence at six month follow-up, although there was a non-significant trend for lower 6-month 
CO validated abstinence in the gradual group compared to the abrupt groups (OR=0.6, 95% CI 
0.3, 1.2). Smokers in the gradual condition were less likely to make a quit attempt than those in 
the abrupt and minimal treatment conditions.  
RCTs comparing nicotine gum versus placebo to facilitate gradual reduction prior to cessation: 
Shiffman 2009 ++ tested the efficacy of nicotine gum in facilitating cessation through gradual 
reduction.  Participants were randomised to receive either gum, at 2mg or 4 mg, or a placebo, 
and were instructed to extend the time to their first cigarette (using the gum) by one hour each 
day. At six month follow-up,  overall those using nicotine gum were almost three times more 
likely than those using placebo to be CO verified abstinent (OR=2.86, 95% CI 1.93, 4.24). These 
differences were more noticeable when comparing those using 4mg gum to those using placebo 
(OR=6.0, 95% CI=2.9, 12.3), although the difference between those using 2mg gum and those 
using placebo also just reached significance (OR=1.8, 95% CI 1.1, 2.9).  
RCT comparing NRT with other types of intervention:  
Martin 1997 + compared behavioural counselling plus exercise, behavioural counselling plus 
nicotine replacement therapy (2mg gum), and standard treatment (which also had behavioural 
components – counselling and attendance at Nicotine Anonymous meeting) in a population of 
recovering alcoholics. There was no statistically significant difference in CO verified quit rates at 
12 months between the three groups; 27%, 27% and 26% respectively. 
                                                          
7
  Nicotine replacement therapy preparations are licensed for adults and children over 12 years, with the exception of Nicotinell® 
lozenges which are licensed for children under 18 years only when recommended by a doctor (BNF accessed online 28 July 2011) 
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Uncontrolled study examining the efficacy of NRT as an aid to gradual cessation:  
Jiménez-Ruiz 2009 – examined the outcome of a programme of progressive reduction, using 
nicotine gum, as a prelude to complete cessation among current smokers who sought treatment 
in a smokers’ clinic but who did not want to quit abruptly. Smokers were instructed to use 2mg 
nicotine gum at recommended levels according to their baseline cigarette consumption, with a 
target of a reduction in the number of cigarettes per day of 50% or more by week 8, and 
abstinence by week 16. Participants also received intensive cognitive behavioural therapy during 
the reduction phase (eight fortnightly one to one sessions). Two groups of smokers were 
compared: those who went to the clinic wanting to quit but not abruptly, and refractory 
smokers, who had failed to quit several times and who were advised to follow a progressive 
reduction programme. CO verified continuous abstinence rates were 39% at the 6 month follow-
up. Differences between the two groups in abstinence rates were not significant. All smokers 
who had successfully quit at 16 weeks continued to use NRT into the abstinence phase but no 
subject used NRT for more than 4 months post quit date. 
Evidence Statements:  
1.1  There is moderate evidence from two randomised controlled trials (RCTs) of no 
significant difference in long-term abstinence rates between gradual and abrupt 
cessation when using NRT (gum or lozenges) (Etter 2009 +, Hughes 2010 ++) 
although the trend favours abrupt cessation. The CO and cotinine validated four 
week quit rate at 12 months was 16.5% for gradual compared to 24.0% for abrupt 
cessation, p=0.14 (Etter 2009 +), The OR for CO validated abstinence at 6 months 
(gradual/abrupt) was 0.6 (95% CI 0.3, 1.2) (Hughes 2010 ++).   
1.2  There is moderate evidence from a large RCT (Shiffman 2009 ++) of a benefit from 
NRT versus placebo at  6 months; this was more marked in the 4 mg gum versus 2 
mg dose rates with ORs of 6.0 (95%CI 2.9,  12.3) and 1.8 (95% CI 1.1,  2.9) 
respectively. Overall OR 2.86 (95% CI 1.93, 4.24). 
 Evidence from two much smaller studies, a quasi-RCT (Martin 1997 +) and an 
uncontrolled before and after study (Jiménez Ruiz 2009 –) is inconsistent. In the 
quasi–RCT mean quit rates for standard treatment versus  behavioural counselling 
with  NRT respectively at  6months were 21% v. 27% (NS)  and at 12 months 26% v 
27% (NS) (Martin 1997 +). In the UCBA study (Jiménez Ruiz 2009 –) 39% reported 
abstinence at 6 months and 68% reported ≥50% reduction in cigarette 
consumption at the end of 8 weeks using a combination of gum and behavioural 
therapy.  The difference in abstinence between participants who wanted to reduce 
to quit versus those who were refractory smokers was not significant (48% vs 32%, 
p=0.8).   
1.3 There is inconsistent evidence from one RCT (Etter 2009 +) and one UBA (Jiménez 
Ruiz 2009 –) of NRT use in the longer term.  Etter 2009 + found that, after 12 
months, 9.2% participants were still using NRT daily (5 pieces per day on average).  
Values were similar in both abrupt and gradual cessation groups. Jiménez Ruiz 
2009 – found that all smokers who had successfully quit at 16 weeks continued to 
use NRT into the abstinence phase but no subject used NRT for more than 4 
months post quit date. 
1.4  There is weak evidence from a single RCT that nicotine gum may be an effective aid to 
reducing cigarettes prior to cessation as daily cigarette consumption in the week 
before the quit date was  12.4 v 21.3 cigarettes /day, p<0.001 (Etter 2009 +). 
The evidence from the RCTs (Etter 2009 +, Hughes 2010 ++, Shiffman 2009 ++) is partially 
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applicable to people in the UK because, although there were no UK-based trials, the 
studies were community-based and are feasible within a UK setting. Martin 1997 + relates 
specifically to recovering alcoholics.  Jiménez Ruiz 2009 – was an intensive intervention 
which is unlikely to be feasible within the UK. 
 
 
 
Q2. How effective are different combinations of NRT products in helping people cut down smoking 
before quitting? 
Evidence Statement:  
2.1 No studies were found that looked at combinations of NRT products for helping people 
to cut down before quitting.  
 
Q3. How effective are ‘nicotine-containing products’ in helping people cut down smoking before 
quitting? 
For the purposes of this review ‘nicotine containing products’ were defined as ‘electronic 
nicotine delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-cigarettes’) and 
topical gels. 
Evidence Statement:  
3.1    No studies were found that looked at the effectiveness of nicotine delivery systems 
(electronic cigarettes) for helping people to cut down before quitting.  
 
 
 
Q4. How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people cut down smoking before quitting? 
Nine studies incorporated behavioural support, including three randomised controlled trials 
(Etter 2011 +, Gunther 1992 –, Hughes 2010 ++), four quasi-randomised controlled trials 
(Cinciripini 1994 +, Cinciripini 1995 +, Martin 1997 +, Marks 2002 +), one trial with partial 
randomisation (O’Leary Tevyaw 2007 –) and one uncontrolled before and after study (Jiménez-
Ruiz 2009 –).  
One study was based in the UK (Marks 2002 +), three in Europe (Etter 2009 +, Gunther 1992 –, 
Jimenez Ruiz 2009 –), five in the USA (Cinciripini 1994 +, Cinciripini 1995 +, Hughes 2010 ++, 
Martin 1997 +, O’Leary Tevyaw 2007 –) and one was a multi-country web-based intervention 
(Etter 2011 +). The community-based trials may be applicable to the UK.   
Both Martin 1997 + and O’Leary Tevyaw 2007 – had very specific populations; recovering 
alchoholics in the former and a US high school in the latter.   
 
Quasi-RCTs comprising a behavioural support element:  
Participants in the experimental condition in Cinciripini’s 1994 + quasi-randomised controlled 
trial were provided with an eight week programme. Participants were instructed to gradually 
reduce the amount of cigarettes smoked, prior to quitting in week 5. During weeks two to five 
cognitive behaviour modification was provided, and during weeks five to nine relapse 
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prevention training was given. Participants in the control condition received an “I Quit Kit” and 
participated in a one hour discussion on its use. The control arm also involved a pre quit 
reduction period, of seven days. The mean number of cigarettes per day gradually declined 
across the pre-quit period in the intervention group; this was not the case in the control group. 
Intervention group subjects smoked an average of 21.39 (9.33), 12.21 (6.72), 8.02 (3.43) and 
5.45 (2.61) CPD in weeks 1 to 4 of the programme. The equivalent figures for the control group 
were 27 (6.76), 28.79 (15.26), 26.71 (11.37) and 20 (14.99). At the 12 month follow-up, CO 
validated abstinence rates were significantly higher in the intervention group than they were in 
the control group. 53% and 41% of the gradual reduction group was abstinent at the 6- and 12-
month follow up periods respectively, compared to 6% of the control group at each time point. 
A further quasi-randomised controlled trial (Marks 2002 +) offered intervention participants a 
combination of ‘30 cognitive behavioural and other relevant methods in a self-help package 
consisting of a handbook (also provided as a cassette tape with relaxing music on the other 
side), reduction cards, a progress chart and other necessary materials’ to guide them towards a 
daily reduction of 50% over the course of 7-10 days. The programme also provided relapse 
prevention support post quit date, to three months. Those in the control group received a 
pocket sized leaflet recommending a staged preparation with an abrupt cessation date, and 
recommendations to phone the national ‘quitline’, GP or health centre for further support. 
Results showed that at the twelve month follow-up, significantly more participants in the 
intervention group were CO-verified abstinent than in the control group. It is worthwhile noting 
that the two programmes were quite different and that this was not a study primarily comparing 
abrupt versus gradual cessation.  
RCT comprising an advice giving element:  
Etter 2011 + emailed intervention participants with the instruction to gradually reduce their 
consumption by half over the next two weeks and then quit. Participants received an 
individually tailored calendar via email with their target cigarette consumption for each day for 
the following two weeks. The control group were emailed the instruction to quit abruptly and 
immediately. There were no significant differences between groups at any follow-up points. 
Note, however, that follow-ups only took place at two and four weeks after the quit date. 
Study comprising RCT element investigating the feasibility of contingency management:  
O’Leary Tevyaw 2007 – investigated the efficacy and feasibility of a contingency management 
protocol for adolescent smokers that included use of a reduction phase. This involved providing 
participants with gift certificates for use in a local shopping centre in return for carbon 
monoxide samples, with the amount of the voucher paid increasing based on the amount of 
carbon monoxide reduction. Participants completed three phases: 1) reinforcement for 
attendance and provision of breath samples (RA phase); 2) a washout phase; and 3) a 
contingency management (CM) phase, with the order of the RA and CM phases being 
counterbalanced between participants. In addition, participants were randomised to one of two 
conditions during the CM phase: 1) abstinence condition, where participants earned 
reinforcement only for carbon monoxide levels indicating abstinence; and 2) reduction 
condition, where participants earned reinforcement for reduction from baseline CO levels for 
the first half of the CM phase, followed by an abstinence contingency for the remainder of the 
phase. Compared with the abstinence group, those in the reduction group demonstrated trends 
for more abstinence readings and had a significantly higher percentage of readings meeting 
criteria for reinforcement during the CM phase. Note that this study had a very small sample 
size as it was primarily designed as a feasibility study. Findings are therefore limited in their 
applicability. 
Uncontrolled study involving behavioural support:  
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As an adjunct to using nicotine gum to aid reduction, participants in Jiménez-Ruiz’s 2009 – study 
also received cognitive behavioural therapy during the reduction phase. At the 6 month post- 
quit follow-up, CO verified continuous abstinence rates were 39%.  Riley 2002 – carried out two 
small before and after studies with a US high-school population. Both employed computerised 
scheduled reduction combined with 7 weekly support meetings (study 1) or brief mid-point 
contact only (study 2). The authors noted that this was just a feasibility study showing that this 
type of intervention is acceptable to an adolescent population; groups were not comparable and 
the results were not generalisable. 
Studies involving a behavioural component across both intervention and control groups where 
it is therefore not possible to infer the effectiveness of the behavioural component:  
In Cinciripini’s 1995 + quasi-randomised trial comparing scheduled and non-scheduled gradual 
approaches to cessation, participants received cognitive behavioural training in week two to 
five.  Cotinine verified abstinence rates at 12 months were 44% (scheduled reduced), 18% (non-
scheduled reduced), 32% (scheduled non-reduced) and 22% (non- scheduled non-reduced); 
p<0.05.   
In Gunther’s 1992 – RCT comparing sudden withdrawal with gradual withdrawal, all participants 
received 12 hours of individual counselling delivered by a behaviour therapist. At 12 months 
follow-up there was a non significant difference in abstinence between sudden and gradual 
withdrawal groups: 51.85% versus 38.71%.  
 Hughes 2010 ++ offered gradual or abrupt cessation counselling plus nicotine lonzenge (2 or 4 
mg) according to intervention arm and also found a non significant difference between arms 
with a trend to favouring abrupt cessation. The OR for CO verified abstinence at 6 months for 
gradual versus abrupt cessation was 0.6 (95% CI 0.3, 1.2). 
Martin 1997 + (in a population of recovering alcoholics) offered behavioural counselling in all 
three arms: modified standard treatment including maintenance counselling and group 
meetings; counselling plus exercise; counselling plus nicotine replacement therapy.  There was 
no statistically significant difference in CO verified quit rates at 12 months between the three 
groups; 26%, 27% and 27% respectively. 
Evidence Statements:  
4.1  There is moderate evidence for the effectiveness of cognitive behavioural therapy versus 
standard therapy from two quasi-RCTs (Cinciripini 1994 +, Marks 2002 +) both in reducing 
the number of cigarettes per day prior to quitting, and in quitting itself. At 12 months 41% 
of the CBT group and 6% of the control group were abstinent, p<0.01.  Figures for 6 
months were 53% and 6%, p< .01 (Cinciripini 1994 +). At 12 months 19.8% (95% CI 13.0, 
28.3) of the contactable CBT group were abstinent compared to 5.8 % (95% CI 2.1, 12.1) 
p<0.0001 (Marks 2002 +). At the same time point 11.5% (95% CI 6.4, 18.5, p<0.0001) had 
reduced their CPD by ≥ 25% compared to 0% in the control group. 
4.2 There is moderate evidence from two RCTs (Gunther 1992 –, Hughes 2010 ++) of a trend 
towards higher abstinent rates for abrupt cessation compared to gradual reduction when 
counselling is offered to both groups (with nicotine as well in Hughes 2010 ++) but the 
findings are not significant. The OR for CO verified abstinence at 6 months for gradual 
versus abrupt cessation was 0.6 (95% CI 0.3, 1.2) (Hughes 2010 ++). At 12 months follow-
up there was a non-significant difference in self reported abstinence between sudden and 
gradual withdrawal groups: 51.85% versus 38.71% (Gunther 1992 –). 
4.3  There is weak evidence from one quasi-randomised trial (Cinciripini 1995 +) suggesting 
that cognitive behavioural therapy combined with advice to schedule and lengthen the 
time between cigarettes may enhance outcomes. Cotinine verified abstinence rates at 12 
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months were 44% (scheduled reduced), 18% (non-scheduled reduced), 32% (scheduled 
non-reduced) and 13% (non-scheduled non-reduced); p<0.05.   
4.4 There is weak evidence from one RCT (Etter 2011 +) to suggest that there may be no 
difference in the effect of advice giving (via web and email) for gradual versus abrupt 
cessation but the follow up period was very short and outcomes were self reported. At 
four weeks 8.8% of the gradual group and 8.7% of the abrupt group reported no puff 
taken in the past 24 hours (p=0.97). 
4.5 There is weak evidence from one RCT (Martin 1997 +) in a population of recovering 
alcoholics that there may be no difference between standard treatment with counselling, 
counselling plus exercise and counselling plus NRT for gradual reduction. CO-verified quit 
rates at 12 months for the three groups were26%, 27% and 27% respectively. 
4.6 There is very weak evidence from a feasibility study (O’Leary Tevyaw 2007 –) suggesting 
that the use of contingency management (a reward for response) may be effective when 
used to support reduction to quit since participants had more abstinent readings in the 
contingency management phase than the reinforcement phase (50% vs 37%).   
4.7 There is very weak evidence from two small before & after studies (Riley 2002 –) that 
computerised scheduled reduction, with or without behavioural support, is acceptable to 
a teenage population. 
This evidence is partially applicable to people in the UK. The use of rewards for response 
(O’Leary Tevyaw 2007 –) is unlikely in this setting. However Marks 2002 + was based in the UK, 
Etter 2011 + was a web-based intervention, and all the other studies were community- or high 
school-based and feasible within a UK setting. One study (Martin 1997 +) was in a specific 
population (recovering alcoholics). 
 
 
Q5. Is there an optimal period for helping people cut down smoking with the aim of quitting? 
The reduction period across the included studies varied from 7-10 days (Marks 2002 +) through 
to 16 weeks (Jiménez-Ruiz 2009 –). Five studies employed reduction periods of between two 
and five weeks (Cinciripini 1994 +, Cinciripini 1995 +, Etter 2009 +, Etter 2011 +, Hughes 2010 
++). Riley 2002 – utilised a seven-week and Martin 1997 + and Shiffman 2009 ++ an eight-week 
schedule. The studies vary considerably in design and it is not possible to identify any 
relationship or trend between the length of the reduction period and outcomes that is not be 
subject to potential confounding by other aspects of the study designs.  
Martin 1997 + found no difference between two different reduction periods, although the 
interventions also differed. CO-verified quit rates at 12 months for the three groups (standard 
treatment with counselling over 4 weeks, counselling plus exercise and counselling plus NRT 
over 8 weeks) were 26%, 27% and 27% respectively. 
None of the other studies compared the effectiveness of different periods of cutting down prior 
to quitting. There was considerable variation in design between the studies and it is not possible 
to identify any relationship or trend between the length of the reduction period and the 
outcomes that is not subject to potential confounding by other aspects of the study designs. 
However, Hughes 2011 – carried out a secondary analysis to examine whether delaying a quit 
attempt was associated with less success. For those assigned to the gradual cessation condition, 
no relationship was found between time to planned quit date, time to actual quit date, or 
quitting after versus on the quit date and six month abstinence. There was also no relationship 
between time to the planned quit date and the likelihood of never making a quit attempt.  
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Evidence Statement:  
5.1 There is weak evidence from a secondary analysis (Hughes 2011 –) and a quasi-RCT  
(Martin 1997 +) to indicate that there is no relationship between time to planned or actual 
quit date and long term abstinence rate among those cutting down prior to quitting.  
5.2 There is no evidence concerning the optimum cuttjng-down period from other studies 
(Cinciripini 1994 +, Cinciripini 1995 +, Etter 2009 +, Etter 2011 +, Hughes 2010 ++, 
Jiménez-Ruiz 2009 –, Marks 2002 +, Riley 2002 –, Shiffman 2009 ++). Reduction periods 
varied from 7 days to 16 weeks. None of the studies explored the effect of the reduction 
time on outcomes and, given the huge heterogeneity between studies, no relationship 
between reduction time and outcomes can be inferred.  
This evidence is partially applicable to people in the UK who smoke because Hughes 2011 – was 
a large community based study that may be feasible in the UK, although a secondary analysis is a 
methodologically weak study. Martin 1997 + looked specifically at recovering alcoholics. 
 
 
Q6. Is it more or less effective to draw up a schedule to help someone cut down smoking with the 
aim of quitting? 
RCTs/Quasi-RCTs comparing scheduled versus non-scheduled reduction: 
Cinciripini 1995 + compared scheduled and non-scheduled gradual and abrupt approaches to 
cessation. Participants were randomised to one of four arms: scheduled reduced (Group A), 
non-scheduled reduced (Group B), scheduled non-reduced (Group C), or non-scheduled non-
reduced (Group D). Participants attended weekly meetings – cognitive behavioural training was 
given in week two to five, and in week five to nine the focus was on maintenance for abstainers 
and cessation for those who had not yet quit. At 12 month follow-up salivary cotinine verified 
abstinence rates were higher in the scheduled groups than in the non-scheduled groups, with 
the highest rate being observed in the scheduled reduced group. Cotinine verified abstinence 
rates at 12 months were 44% (Group A), 18% (Group B), 32% (Group C) and 22% (Group D); 
p<0.05. Participants in the scheduled reduced groups exhibited significantly reduced tension 
from week 8 to 6 months follow up (no data provided). 
Martin 1997 + a study in recovering alcoholics, instructed those in the standard treatment group 
to carry out three large-scale smoking rate reductions by one third each week prior to the target 
quit date in week four. This compared with those in the two intervention groups who made 
more gradual and unscheduled reductions over an eight week period. CO verified quit rates at 
12 months were not statistically different between the three groups. 
Study comparing different types of schedule:  
In an RCT comparing gradual versus abrupt cessation approaches, Hughes 2010 ++ 
recommended that participants in the gradual reduction group reduced by 25% in the first 
week, 50% in the second week, and 75% in the third week, although each smoker chose his or 
her own goal and rate of progress. Three different reduction methods were described to 
participants: a) scheduled reduction (SR) in which smokers gradually increase the time between 
cigarettes; b) hierarchical reduction-easiest first (HR-E) in which smokers eliminate cigarettes 
from easiest to hardest to give up; and c) hierarchical reduction hardest first (HR-H) in which 
they eliminated the hardest to give up cigarettes first. Sixty percent of participants chose SR, 
25% chose HR-E, 11% chose HR-H, and in 4% it was unclear which method they chose. Reduction 
and abstinence rates did not appear to differ across the initially chosen methods and the 
authors’ clinical observation was that the large majority of smokers did not exclusively use their 
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chosen method of reduction, but instead used several methods or reduced without using any of 
the described methods. Therefore the results were pooled across all the methods. 
Evidence Statements:  
6.1 There is weak evidence from one quasi-RCT for scheduled versus non-scheduled 
reduction. (Cinciripini 1995 +) found that cognitive behavioural therapy combined 
with advice to schedule and lengthen the time between cigarettes enhanced 
outcomes.  Cotinine-verified abstinence rates at 12 months: 44% (scheduled 
reduced), 18% (non-scheduled reduced), 32% (scheduled non-reduced) and 22% 
(non-scheduled non-reduced); p<0.05.  
6.2 There is weak evidence from one large RCT (Hughes 2010 ++) and one quasi-RCT 
(Martin 1997 +) that the type of smoking reduction schedule used does not make a 
difference.  Hughes 2010 ++reported that reduction and abstinence rates did not 
appear to differ across the initially chosen methods (formal schedule, giving up 
‘easiest’ cigarettes first, giving up ‘hardest’ cigarettes first) so the results were 
pooled across all the methods. Martin 1997 + found no difference between 
different intervention and scheduled reduction methods. CO-verified quit rates at 
12 months for the three groups (standard treatment with counselling over 4 weeks, 
counselling plus exercise and counselling plus NRT over 8 weeks) were26%, 27% 
and 27% respectively. 
This evidence is partially applicable to people in the UK since the studies are community 
based and feasible in UK settings. One study (Martin 1997 +) was in a specific population 
(recovering alcoholics). 
 
 
 
Q7. Do some tobacco harm-reduction approaches have a differential impact on different groups 
(for example, people of different ages, gender, socioeconomic status or ethnicity)? 
Only two studies, both RCTs, examined differences across groups. Etter 2011 + compared 
findings according to age and sex, whilst Marks 2002 + examined differences according to 
gender and socio-economic group. Neither study found evidence of a difference between the 
groups. 
Evidence Statements:  
7.1 There is moderate evidence from two RCTs (Etter 2011 +, Marks 2002 +) to suggest that 
tobacco harm reduction approaches do not appear to have a differential impact on 
abstinence rates (Etter 2011 +, Marks 2002 +) or CPD (Marks 2002 +) according to age, 
gender (Etter 2011 +, Marks 2002 +) or socioeconomic group (Marks 2002 +).  
This evidence is applicable to people in the UK since Marks 2002 + was based in the UK and Etter 
2011 + was web-based and is feasible in a UK setting. 
 
Q8. Are there any unintended consequences from adopting a tobacco harm-reduction approach, 
for example, does it deter people from trying to stop smoking? 
In their RCT comparing gradual cessation, abrupt cessation, and minimal treatment, Hughes 
2010 ++ reported that smokers in the gradual condition were less likely to make a quit attempt 
than those in the abrupt and minimal treatment conditions. In the gradual condition, for every 
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week delay to quit date the probability of lapsing increased by 19%. In a secondary analysis of 
this study, Hughes 2011 – found that 57% of the gradual group had either quit after their 
planned date or did not make a quit attempt at all, which was somewhat higher than those in 
the abrupt (29%) and control (33%) group. 
Etter's 2009 + RCT tested whether starting nicotine gum four weeks before the quit date 
alongside reducing the number of cigarettes per day improved abstinence rates compared to 
starting gum on the quit date.  The authors reported that after 12 months, 9.2% of participants 
were still using nicotine gum daily. These values were similar in both groups. 
Cinciripini 1995 + reported on withdrawal symptoms and tension during the quit week. From 
quit week through the follow-ups (except Week 7), scheduled reduced participants experienced 
significantly fewer withdrawal symptoms than the other groups, who did not significantly differ 
from each other (no data provided). During the quit week (Week 5), scheduled reduced 
participants reported the least amount of tension and non-scheduled non-reduced participants 
reported the most. Thereafter, tension scores fell for all groups, but those for scheduled 
reduced participants remained significantly below the others from Week 8 through the 6 month 
follow-up. The remaining groups did not differ (no data provided). 
Evidence Statements:  
8.1 There is moderate evidence from one large well conducted RCT (Hughes 2010 ++) to 
suggest that gradual reduction may be associated with a decreased likelihood of making a 
quit attempt, and that delaying the quit attempt may lead to an increased risk of relapse. 
However it should be noted that the overall difference in 6-month quit rate from abrupt 
versus gradual NRT-aided cessation was not statistically significant (see statement 1.1).   
For every week delay to quit date the probability of lapsing increased by 19%.  In a 
secondary analysis of this RCT (Hughes 2011–) 57% of the gradual group had either quit 
after their planned date or did not make a quit attempt at all, which was somewhat higher 
than those in the abrupt (29%) and control (33%) groups, although this relationship was 
not tested statistically. 
8.2 There is weak evidence from one RCT in relation to NRT (Etter 2009 +) suggesting that 
there is no increased risk of long term use when NRT is first used as an aid to reduction 
compared to when it is used simply as an aid to abrupt cessation. After 12 months 9.2% of 
participants were using nicotine gum daily and values were similar in both groups. 
8.3 There is weak evidence from one RCT (Cinciripini 1995 +) that people cutting down to quit 
using a scheduled reduced approach experience fewer withdrawal symptoms in quit and 
post-quit weeks and less tension in the quit week compared to the other reduction 
approaches tested (no data provided). 
This evidence partially applicable to people in the UK since the studies were community based 
and are feasible in UK settings. 
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Comparison with two previous systematic reviews  
Authors of two systematic reviews found within the literature search aimed specifically to look at 
cutting down to quit interventions (Lindson 2010, Wang 2008). Both studies were unpicked for 
relevant primary studies as well as being briefly summarised here.   
The systematic review by Wang 2008 considered seven studies. The authors noted that no RCTs 
specifically addressing cutting down to quit were identified (search to July 2006) but inclusion criteria 
were broad enough to include some reduction studies. Two of the included RCTs remain unpublished 
and five appear to meet the inclusion criteria for the long-term harm reduction review, review 3, and 
are being considered within that review (Batra 2005, Bolliger 2000, Etter 2004, Rennard 2006, 
Wennike 2003). 
Lindson 2010 carried out a systematic review of ten studies (3,760 participants) of reduction prior to 
quitting versus abrupt quitting. The literature search was completed in November 2009.  
Pharmacotherapy, self help and behavioural support were all considered.  None of the studies 
reviewed by Wang 2008 were included in the review.  
Of the studies considered by Lindson 2010, two remain unpublished (Jerome 1999, Riley 2005), one 
was published in Spanish (Roales-Nieto 1992) and three were published before 1990 (Flaxman 1978, 
Curry 1988, Cummings 1988) and are thus excluded from this review. The four remaining studies are 
all considered in the results section of this review (Cinciripini 1995, Etter 1999, Hughes 2009 [now 
published 2010/11] and Gunther 1992.    
Lindson 2010 found that neither reduction nor abrupt quitting was found to have superior 
abstinence rates at six months or more when all the studies were combined in a meta-analysis 
(RR=0.94, 95% CI 0.79, 1.13). This was the case regardless of whether pharmacotherapy was used 
(RR=0.87, 95% CI 0.65, 1.22), studies included behavioural support (RR=0.87, 95% CI 0.64, 1.17) or 
self-help therapy (RR=0.98, 95% CI 0.78, 1.23).  Authors were unable to draw conclusions about the 
difference in adverse events between interventions from the intervention studies examined. 
They concluded that reducing cigarettes smoked before quit day and quitting abruptly, with no prior 
reduction, produced comparable quit rates; therefore patients can be given the choice to quit in 
either of these ways. Reduction interventions can be carried out using self-help materials or aided by 
behavioural support, and can be carried out with the aid of pre-quit NRT. They also proposed further 
research to investigate which method of reduction before quitting is the most effective, and which 
categories of smokers benefit the most from each method. 
 
Supplementary evidence from four smoking cessation studies with data on pre-quit reduction 
 
Following discussion with NICE, four studies that did not meet inclusion criteria for the review have 
been retained for information since they contained data that might be of contextual interest on pre-
quit reduction (Brown 2003, Cropsey 2011, Hughes 1999, Hughes 2004).  
The interventions were designed for smoking cessation (rather than as cut down to quit). However 
they provide some outcome data on pre-quit reduction. As the studies are outside the systematic 
review they are not discussed in the results section or detailed in the Evidence Tables (Appendix A); 
but data are provided in Appendix H. 
One was a non randomised study (Brown 2003) and three were secondary analyses of RCTs (Cropsey 
2011, Hughes 1999, Hughes 2004) and thus have considerable potential for bias.  
Brown 2003 looked at the effect of motivational interviewing (MI) to support smoking cessation in 
adolescent smokers hospitalised for psychiatric and substance use disorders in the US. The authors 
concluded that MI might be more effective for adolescents with little or no intention to change their 
smoking habits, but less so for those with pre-existing intentions to cut down or quit. 
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Cropsey 2011 carried out an NRT and behavioural smoking cessation intervention for female 
prisoners in the US. This secondary analysis measured the differences in smoking success based on 
any pre-quit reduction by participants in the 6-month wait-listed group. Smokers who showed no 
pre-quit reduction had significantly lower quit rates early in cessation treatment but there were no 
differences at long term follow up (12 months). 
Hughes 1999 carried out a secondary analysis of a huge smoking cessation trial (COMMIT) by 
analysing 1410 subjects who smoked at both baseline and 2-year follow up. The odds ratio for 
successful cessation at 4 years for those who had reduced smoking by ≥ 50% at 2-years, compared to 
those who had increased their smoking by ≥ 5% was not significant. 
Finally Hughes 2004 conducted a secondary analysis of 1722 participants in the Lung Health Study. 
All had early lung disease and were still smoking at 1-year follow up. Overall they found that 
reduction predicted neither an increased nor a decreased probability of future cessation.  Of subjects 
who did not reduce smoking at 1 year, 3% had quit by year 5. Of those who had reduced by 75-99% 
at year 1, 4% had quit by year 5. Relapse was common. In all cases (no reduction and various % 
reduction groups) quit rates at 2 years were higher than those at 5 years (see Appendix H for details). 
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5. DISCUSSION 
This systematic review found few intervention studies that were designed to look specifically at cut 
down to quit interventions. Furthermore, those studies varied considerably in methodology, in the 
interventions used, the outcomes measured and the participant populations. 
The quality of the included studies was moderate at best. Only two studies were rated as having a low 
risk of bias (Hughes 2010 ++, Shiffman 2009 ++) and four were rated as being significantly biased 
(Gunther 1992 –, Jimenez-Ruiz 2009 –, O’Leary Tevyaw 2007 –, Riley 2002 –); as was a secondary 
analysis of the Hughes 2010 data (Hughes 2011 –).  
The two RCTs of highest quality involved the use of NRT (Hughes 2010 ++ and Shiffman 2009 ++). Lead 
authors of both studies had strong ties to manufacturers of smoking cessation products and Shiffman 
2009 ++ was funded and co- authored by a pharmaceutical company. Authors clearly declared sources 
of funding and any potential conflicts of interest. However, a 2003 meta-analysis of RCTs included in a 
Cochrane review of smoking cessation interventions concluded that “Compared with independent 
trials, industry-supported trials were more likely to produce statistically significant results and larger 
odds ratios. These differences persisted after adjustment for basic trial characteristics.” (Etter 2003) 
The authors suggested that this difference may be the result of publication bias.  
Even in the relatively small number of included studies, there was a wide variation in the range of 
outcomes; both in timeframes (four weeks to twelve months) and assessment methods (self-reported, 
CO or cotinine verified). Furthermore, there did not appear to be consistency even within methods. CO 
measures to assess abstinence varied from ≤5ppm to ≤10ppm across the different studies. If the 
debate on this topic is to move forward, outcome measures need to be agreed and standardised.  
Participant motivation was sometimes difficult to ascertain and few studies were in participants who 
wanted to quit but did not want to do so abruptly. For this reason, the scope of the review was 
extended to include all individuals who participated in a cut down to quit study. 
Only one study was conducted in the UK (Marks 2002 +), and it is difficult to assess how applicable the 
other studies are likely to be although it seems reasonable to assume community-based programmes 
in the USA and Europe are feasible within a UK setting. Some interventions had significant resource 
implications (12 hours counselling for Gunther 1992 –, eight clinic visits for Jimenez-Ruiz 2009 –, 
incentive payments for O’Leary Tevyaw 2007 –, and/or very specific populations (alcoholics in Martin 
1997 +, US high school students in O'Leary Tevyaw 2007 – and Riley 2002 –).  
In light of the huge design variation between the studies included in this review, meta-analyses were 
not considered appropriate. Consequently, the results of the analyses carried out for this review are 
provided in Appendix I for information, although they are not discussed in the main body of the text.  
In a recent Cochrane review Lindson 2010 did undertake meta-analyses for their collection of studies 
and their results are summarised in Section 4.9. 
Despite the differing approaches to analysis by statisticians and the differences in included studies, the 
narrative findings of this review and that by Lindson 2010, which looked specifically at gradual versus 
abrupt quitting, both indicate there is no evidence of difference between gradual reduction and abrupt 
cessation methods.  
Overall, the data suggest it is reasonable to give those who are looking to give up smoking the choice 
of whether they cut down gradually or quit abruptly. Also to provide choice over the method of 
reduction (scheduled, over a short or long time period). However, these conclusions need to be set 
against the findings from Hughes 2010 ++. This study suggests a reduction approach may allow 
smokers to delay their quit attempts and increase the likelihood of relapse. There are indications that 
NRT support may enhance the ability of smokers to quit abruptly over purely behavioural approaches.  
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Although some study samples were from disadvantaged groups there was very little evidence on 
differential impact between groups. 
Although there is useful contextual information from the studies which is likely to be enhanced in due 
course by the findings from the long term reduction review (Review 3) and barriers and facilitators 
review (Review 4), further research is clearly needed: more high quality studies that are adequately 
powered with consistent outcome measures to help answer the questions of what techniques work 
best and for whom (both in terms of participant motivation and particular population groups). 
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APPENDIX A – INCLUDED STUDIES - EVIDENCE TABLES  
First author and 
year:   
Cinciripini 1994 
Aim of study: 
To compare the 
efficacy of scheduled 
smoking reduction 
with a minimal self-
help treatment 
control 
Study Design : 
Individual quasi-
randomised 
controlled trial 
Quality score: 
+ 
External validity 
score: 
+ 
 
Setting: 
Texas, USA (developed) 
Participants: 
34 smokers (19 males, 15 
females) recruited 
through newspaper and 
radio advertisements. 
Subjects had no history of 
a psychiatric disorder or 
major medical illness.  All 
participants smoked more 
than one packet of 
cigarettes a day. 
Mean age was 43.5 years 
in group 1 (intervention) 
and 38.2 years in group 2 
(control) 
Inclusion: 
Not specified.  
Exclusion: 
Not specified 
 
Participants' motivations 
unknown 
Method of allocation: 
Block randomisation – successive 
sequences of five subjects were 
alternately assigned to the two groups 
Intervention(s): 
Eight weekly sessions consisting of 
baseline, cessation, and relapse 
prevention phases. Baseline: 
participants self-monitored smoking 
and the total hours spent awake.  
Cessation (3 weeks): participants 
progressively increased inter-cigarette 
intervals, thereby gradually reducing 
total daily intake of nicotine. 
Participants were expected to quit on a 
target date at the end of this period. 
Relapse prevention: behavioural 
rehearsal of non-smoking skills in a 
relapse prone environment. 
Control: 
Participants given American Cancer 
Society “I Quit Kit” and participated in 
a one-hour discussion on use of the kit, 
which advocated a 7-day reduction to 
quit schedule. 
Sample sizes: 
34 (17 in each group): 
I =  8 males and 9 females  
C = 11 males and 6 females  
Baseline comparisons: 
Age, CPD, nicotine yield from 
cigarettes, and cotinine levels reported 
for each group at baseline but no 
comparisons to examine differences. 
Study power: 
No power calculation reported. 
Intervention delivery: 
Authors are university researchers 
Primary outcomes: 
Self reported two week point 
prevalent CO-verified 
abstinence (< 8 ppm) at 6 and 
12 months follow up. 
Other measures:  Mean CPD 
weeks 1-4 and self reported 24-
hour point prevalent CO-
verified abstinence (< 7 ppm) at 
weeks 5 & 9. 
Follow-up periods: 
6 and 12 months 
Method of analysis: 
χ² comparisons between the 
groups on percentage of 
subjects reporting abstinence 
at each assessment point. 
Primary: 
At 12 months 7 out of 17 (41%) of the 
intervention group and 1 out of 17 
(6%) of the control group were 
abstinent (χ
2
=5.65, p<0.01). 
At 6 months 9 out of 17 (53%) of the 
intervention group and 1/17 (6%) of 
the control group were abstinent 
(χ2=6.90, p<0.01). 
Cigarettes per week in weeks 1-4 as 
mean ( standard deviation):  
I: 21.39(9.33), 12.21(6.72), 
8.02(3.43), 5.45(2.61) 
C: 27(6.76), 28.79(15.26), 
26.71(11.37), 20(14.99). 
Attrition: 
At the 12 month follow-up period 
one person in each group was unable 
to provide CO verification of their 
abstinence status. The authors report 
that since both of these people were 
CO verified abstinent from the target 
quit date through to the 6 month 
follow-up, they were counted as 
abstainers at 12 months. 
 
Limitations (author):  
An initial test of treatment 
efficacy and a larger scale 
replication would be 
necessary to allow for 
further confidence in the 
results. 
Limitations (review team): 
Inappropriate analysis – see 
attrition section. Very small 
sample size.  Limited 
baseline data.  Methods of 
analysis poorly defined, 
with no adjustment for 
multiple testing. 
Verification method 
unclear: text refers to C0₂ 
data (<8ppm); table refers 
to CO data (<7ppm) 
Evidence gaps: 
Would this kind of 
approach be effective in a 
larger and more 
representative sample? 
Funding sources: 
Texas Affiliate of the 
American Heart Association 
and the National Institute 
of Drug Abuse. 
Applicable to UK? 
A small study although this 
type of programme could 
be delivered in a UK setting. 
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First author and 
year:   
Cinciripini 1995 
Aim of study: 
To compare the 
efficacy of scheduled 
and non-scheduled 
gradual and abrupt 
approaches to 
nicotine withdrawal 
(i.e. cessation) 
Study Design : 
Individual quasi-
randomised  trial 
Quality score: 
+ 
External validity 
score: 
+ 
 
 
 
 
 
 
 
 
 
Setting: 
Galveston-Houston, USA 
(developed) 
Participants: 
128 community dwelling 
daily smokers.  
Gender: 42% male, 58% 
female 
Inclusion: 
A 3-year smoking history; 
consumption of ≥ 15 
cigarettes per day. No 
current cessation 
treatment, no current 
psychiatric disorder or 
uncontrolled systemic 
illness.  
Exclusion: 
Those with SCL-90-R 
(Symptom Check List-90—
Revised) t scores > 65. 
 
Participants' motivations 
unknown. 
Method of allocation: 
Not stated 
Intervention(s): 
Scheduled reduced (Group A) 
participants instructed to smoke only 
at specific times of the day, and inter-
cigarette interval progressively 
lengthened.  
Non-scheduled reduced (Group B) 
participants gradually reduced number 
of cigarettes smoked per day but inter-
cigarette interval was self-selected. 
Scheduled non-reduced (Group C) 
participants told to smoke at specific 
times of the day but no adjustment 
made to inter-cigarette interval or 
consumption frequency. 
Control: 
Non-scheduled non-reduced (Group D) 
participants received no manipulation 
of either smoking frequency or inter-
cigarette interval.  
Cognitive behavioural training and 
relapse prevention advice given to all 
four groups. Cognitive behavioural 
training given in weeks 2-5.  Meetings 
in weeks 5-9 emphasised maintenance 
for abstainers and cessation for others. 
Sample sizes: 
128 participants, 32 in Group A, 33 in 
Group B, 31 in Group C, 32 in Group D. 
Baseline comparisons: 
No significant differences.  
Study power: 
No power calculation provided. 
Intervention delivery: 
Authors are university researchers 
Primary outcomes: 
Primary and secondary 
outcomes were not specified.  
The main outcomes were 
smoking abstinence and 
tobacco consumption: these 
were measured using the 
Smoking Status Questionnaire 
(SSQ, developed for this study), 
abstinence verified with 
salivary cotinine (<14ng/ml) 
and expired CO (<6ppm). 
Withdrawal symptoms [Hughes 
(Minnesota) Withdrawal 
Symptoms Checklist], mood 
states [The Tension and Fatigue 
subscales from the Profile of 
Mood States] and self efficacy 
were also measured. 
Follow-up periods: 
1, 6 and 12 months post 
treatment.  
Method of analysis: 
MANOVAs for tobacco 
consumption, with significant 
outcomes being followed by 
planned contrasts.  
Abstinence was evaluated using 
logistic regression analyses and 
χ2 comparisons. A series of 
planned contrasts were also 
conducted to compare both 
scheduled groups (Groups A 
and C) against both non-
scheduled ones (Groups B and 
D). 
 
Primary: 
Salivary cotinine verified abstinence 
rates at 12 months were 44% in 
group A, 18% in group B, 32% in 
group C, and 22% in group D ( 
p<0.05). 
Cigarettes consumed and cotinine 
concentrations were significantly 
lower for all groups at 12 months 
than at baseline. 
Cotinine values (standard deviations) 
at 12 months were 132.8 (50.6) 
ng/ml for group A, 310.2 (201.4) for 
group B, 245.3 (190.6) for group C, 
and 289.6 (206.0) group D 
(significance values not reported). 
At six months cotinine verified 
abstinence rates were 41% (group A), 
12% (group B), 29% (group C), and 
13% (group D), (p<0.001). 
Cigarette consumption and cotinine 
fell significantly for all groups from 
baseline through to the quit week.  
Groups A and B (reduced groups) 
decreased consumption significantly 
more than groups C and D (non-
reduced groups).  
Consumption in the quit week 
averaged 4.5 (group A), 7.4 (group B), 
11.9 (group C), and 15.2 cigarettes 
per day (significance not reported). 
From quit week through the follow-
ups (except Week 7), scheduled 
reduced participants experienced 
significantly fewer withdrawal 
symptoms than the other groups, 
who did not significantly differ from 
each other (no data provided).  
During the quit week (Week 5), 
scheduled reduced participants 
Limitations (author):  
The authors did not identify 
any limitation 
Limitations (review team): 
Gaps in reporting of study 
design, eg unclear 
randomisation method and 
allocation, very little 
description of eligible and 
recruited populations. 
Evidence gaps: 
Study doesn’t consider 
participants’ preferences 
for gradual versus abrupt 
cessation or fixed versus 
non-fixed schedules. 
Funding sources: 
National Institute of Drug 
Abuse. 
Applicable to UK? 
Yes, potentially feasible. 
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reported the least amount of tension 
and non-scheduled non-reduced 
participants reported the most. 
Thereafter, tension scores fell for all 
groups, but those for scheduled 
reduced participants remained 
significantly below the others from 
Week 8 through the 6 month follow-
up. The remaining groups did not 
differ (no data provided). 
Attrition: 
Not reported 
First author and 
year:   
Etter 2009 
Aim of study: 
To test whether 
starting Nicotine 
polacrilex gum 4 
weeks before quit 
date improved 
abstinence rates 
compared to starting 
treatment on quit 
date. 
Study Design : 
Individual 
randomised 
controlled trial 
Quality score 
+ 
External validity 
score 
++ 
 
Setting:  
 Geneva and Vaud 
Cantons of Switzerland 
(developed). 
Participants: 
314 community dwelling 
daily smokers (≥ 15 
cigs/day) aged ≥18. 
Gender: 64.9% men (I), 
52.% (C) 
Age: 42.0 (I), 44.1 (C) 
Years of schooling: 14.5 
(I), 14.7 (C) 
Inclusion: 
Participants had to be 
committed to quit at a 
pre-set future date and 
agree to chewing ≥ 10 
pieces of nicotine gum 
per day. 
Exclusion: 
Exclusion criteria included 
lactation, current or 
planned pregnancy, 
unstable angina pectoris, 
and myocardial infarction 
or stroke in the past 3 
Method of allocation: 
Computer-generated random numbers 
Intervention(s):  
Pre-cessation treatment group was 
given nicotine polacrilex gum (4mg 
unflavoured) for 4 weeks before and 8 
weeks after target quit date and was 
recommended to decrease their 
cigarette consumption by 50% before 
quitting, although no schedule was 
specified 
Control: 
Nicotine polacrilex gum (4mg 
unflavoured) for 8 weeks after target 
quit date and was recommended to 
quit abruptly. 
Both groups were instructed to use ≥ 
10 pieces of nicotine gum per day, sent 
a booklet and provided with the url for 
a smoking cessation website. 
Sample sizes: 
Eligible:349 
Intervention: 154 
Control: 160 
Baseline comparisons: 
Balanced other than more men in 
Primary outcomes: 
Abstinence (self report) and 
CPD at 3 days, 8 weeks. 
Abstinence (self report, salivary 
cotinine ≤10ng/ml, CO 
≤10ppm) at 12 months 
Follow-up periods: 
3 days, 8 weeks, 12 months 
post target quit date. 
Method of analysis: 
χ² tests and odds ratios to 
compare proportions.  
 
Primary:  
At the 12 months survey there was 
no statistically significant difference: 
(24.0% [37 of 154] for biochemically 
validated 4-week quit rate for abrupt 
and 16.5% [18 of 109] for gradual, 
P=0.14).  [8 week data also available.] 
Daily cigarette consumption during 
the week before the quit date, as 
reported on the 3-day survey, was 
lower in the pre-cessation treatment 
group than in the usual care group 
(12.4 vs 21.3 CPD; P<0.001).  
After 12 months, 9.2% of participants 
were still using NRT daily. Gum users 
chewed on average 5 pieces per day. 
These values were similar in both 
groups. 
Attrition: 
11.8% attrition at 12 month survey; 
16.1% for salivary cotinine measures; 
44.5% CO for those with +ve cotinine. 
Results at 12 months not significant.  
No process info on optimal period, 
schedule or SES.  No ‘serious’ adverse 
events reported during treatment. 
Limitations (author):  
 Target quit date was 
delayed by two months.  
 One third of participants 
in the pre-cessation 
treatment group quit 
abruptly and a few in the 
other group quit 
gradually. 
Limitations (review team): 
No power calculation or 
blinding. 
Evidence gaps: 
Comparison between gum 
and patch in this setting. 
Funding sources: 
Grant 3200-067835 from 
the Swiss National Science 
Foundation. Nicotine gum 
provided at no charge by 
Pfizer. 
The Institute of Social and 
Preventive Medicine (Etter) 
received funding from 
Novartis and Pfizer to 
develop internet-based 
smoking cessation 
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months. Patients with 
substance use disorder or 
a psychiatric condition 
and those with a dental or 
mouth problem were 
excluded if indicated by a 
physician. 
control  
Study power: 
No power calculation provided. 
Intervention delivery:  
Authors are university researchers  
 programs.  
Etter and Cornuz have 
acted as advisers to Pfizer. 
Applicable to UK? 
Yes 
First author and 
year:   
Etter 2011 
Aim of study: 
To compare abrupt 
and gradual smoking 
cessation. 
Study Design : 
Individual 
randomised 
controlled trial 
Quality score: 
+ 
External validity 
score: 
+ 
 
Setting:  
French language internet 
website: stop-tabac.ch 
Participants: 
974 daily smokers aged 
≥18 who were interested 
in quitting and responded 
to a website survey. 
Inclusion: 
No preference for abrupt 
or gradual cessation. 
Commit to quit as 
requested. 
Respond to follow up 
surveys. 
Exclusion: 
Declined data storage. 
Former/non/daily/never 
smoker. 
Did not provide email 
address. 
 
Method of allocation: 
Computer-generated randomised 
numbers.  
Intervention(s): 
Group 1: Sent the instruction (on the 
web page and by e-mail) to quit 
abruptly and immediately. 
Group 2: Sent the instruction to 
gradually reduce their cigarette 
consumption by half over the next 2 
weeks and then quit. They received by 
e-mail an individually tailored calendar 
sent by email with target cigarette 
consumption for each day of the next 2 
weeks. For each participant, the 
computer calculated a linear reduction 
in cig./day, ending with a 50% 
reduction on the day before the target 
quit date. 
Sample sizes: 
Eligible: 19,025 
Of these 974 participants did not have 
a preference for gradual or abrupt 
quitting and so were randomised as 
follows: 
Immediate quit: 472 
Reduce and quit: 502   
(Those who did have a preference 
were allocated to their preferred 
group; separate analyses were done 
for these participants). 
Baseline comparisons: 
Primary outcomes: 
Quit rate at follow-up 
Follow-up periods: 
Two and four weeks after 
target quit date. 
Method of analysis: 
χ² tests to compare proportions 
and Kruskal–Wallis χ² tests to 
compare medians. Data were 
analyzed “intention to treat” 
(including all participants and 
counting dropouts as smokers). 
Primary: 
Abstinence rates were similar 
between abrupt and gradual groups 
for all follow-up durations (This 
outcome was unchanged when data 
were analyzed separately in  
subgroups defined by dependence 
level, craving,  motivation, 
confidence, depression, method used 
for last quit attempt, age or sex).     
At 4 weeks: abrupt 8.7% of abrupt 
and 8.8% of gradual smokers 
reported no puff in past 24 hours (χ² 
0.0, p=0.97). 3.0% and 4.4% 
respectively reported no puff in past 
4 weeks (χ² 1.4, p=0.24). [Two week 
results are also reported] 
Attrition: 
Not stated, although the authors 
note it was high. An ITT analysis was 
conducted. 
 
Limitations (author):  
Study conducted in visitors 
to a smoking cessation 
website who were highly 
motivated to quit. 
Sample contained more 
women and heavier 
smokers. 
Drop-out rates were high. 
No biochemical verification 
of abstinence. 
Short term results only. 
Limitations (review team): 
Authors do not report 
whether respondents were 
using any method(s) of 
support to quit. 
Evidence gaps: 
Lack of long term evidence 
Funding sources: 
The study received no 
external funding. 
Etter consulted for Pfizer, a 
manufacturer of smoking 
cessation medications, in 
2006–2007 (on the Swiss 
varenicline advisory board), 
and received medications 
for a clinical trial from 
Pfizer in 2006. 
Applicable to UK? 
Yes 
THR 2.3 Review 2 - Effectiveness of tobacco harm reduction approaches with the intention of quitting, with and without 
assistance 
 
 
45  
 
No comparison between groups. 
Study power: 
Calculated that 950 participants would 
provide sufficient power at 80% with a 
significance level of 0.05, based on an 
expected quit rate of 20% in the 
abrupt group and on the assumption 
that abrupt would be more effective 
than gradual with a risk ratio of 1.4. 
Intervention delivery: 
Not stated. Author is an academic. 
First author and 
year:   
Gunther 1992 
Aim of study: 
To determine if the 
sudden cessation 
method is more 
successful than the 
gradual method in 
addictive smokers 
with regard to a 
relapse during the 
follow-up period of 1 
year. 
Study Design : 
Individual 
randomised 
controlled trial 
Quality score: 
– 
External validity 
score: 
+ 
 
Setting: 
Community-based 
smokers’ counselling 
centre, Austria.  
Participants: 
110 smokers who 
consulted the counselling 
centre between Feb-Dec 
1988. 
Inclusion: 
Psychiatrist-determined 
nicotine dependence as 
per DSM- III-R. 
Value of ≥6 on the 
Fagerstrom Questionnaire  
Exclusion: 
Patients with psychiatric 
disorders and medical 
illness (especially cardiac 
diseases or cancer) 
 
Participants' motivations 
unknown. 
Method of allocation: 
Computer generated randomisation 
list. 
Intervention(s): 
Group 1: Sudden withdrawal 
Group 2: Gradual withdrawal 
All patients were treated in individual 
sessions by a behaviour therapist. They 
received 12 hours of counselling of 
which the first hour was used for 
history-taking.  
Group 1: Patients were made familiar 
with self-control techniques in the first 
five sessions after history-taking and a 
date was agreed for sudden cessation. 
After the date had been fixed, the 
remaining five sessions were used for 
follow-up treatment. [Note: this 
appears to add to a maximum of 11 
sessions] 
Group 2: the number of cigarettes was 
reduced in the gradual withdrawal 
therapy. Depending on the initial 
consumption, the number of cigarettes 
per week was reduced by 5- 10 
cigarettes. Parallel to this, the patients 
were taught techniques of behaviour 
therapy and cognitive self-control.  
Primary outcomes: 
Self-reported abstinence at 12 
months and time of relapse 
Secondary outcomes: 
Self-reported cigarette 
consumption 
Follow-up periods: 
End of therapy and 12 months 
post therapy. 
Method of analysis: 
Wilcoxon test comparing 
groups for cigarette 
consumption at end of therapy 
and 12 month follow-up. 
Abstinence and time of relapse 
were compared by χ
2
test. 
Kruskal-Wallis test to compare 
smoking behaviour of groups 
prior to the start of the 
therapy, and CPD at start of 
therapy and 12 month follow-
up. 
Primary:  
At 12 months follow-up, 51.85% of 
group 1 (sudden withdrawal) and 
38.71% of group 2 (gradual 
withdrawal) reported abstinence. 
The difference is not significant.  
Those who relapsed started using 
nicotine again 2.31±1.96 months 
after the end of therapy in group 1, 
and 4.29±2.84 months after the end 
of therapy in group 2 (χ
2
=0.36, p 
value not reported)  
Secondary: 
Data for cigarette consumption at 1-
year follow-up showed that patients 
in group 1 smoked significantly more 
per day than patients in group 2. 
(25.39± 8.53 and 18.47 ±8.17 CPD 
respectively, p≤.05)). 
Comparison of cigarette 
consumption at baseline and at 12 
month follow-up in each group 
showed that for group 1 there was 
no significant difference between the 
two time points (27.08±7.21 and 
25.39±8.53, W=0.34, n.s.), whereas 
for group 2 the number of cigarettes 
smoked at follow-up was significantly 
Limitations (author):  
No biochemically validated 
measures of abstinence 
Limitations (review team): 
No baseline data for 
participants. No power 
calculation. No ITT – 
analysis based on 58/110 
who completed therapy 
and responded to 
questionnaire. 
Evidence gaps: 
None reported. 
Funding sources: 
Not reported. 
Applicable to UK? 
Yes but length of therapy 
period is not current 
practice. 
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Successful clients of both groups 
subsequently had three additional 
booster sessions at monthly intervals. 
CO levels were measured regularly.  
Urinary cotinine levels were 
determined in the last therapeutic 
session and at the follow-up 
appointments.  
Sample sizes: 
110 eligible patients of the 148 treated 
in the counselling centre in the 
timeframe. 
55 allocated to each group. 
Baseline comparisons: 
No comparisons reported. 
Study power: 
No power calculation reported. 
Intervention delivery: 
Smoking counselling centre behaviour 
therapists. 
less than at baseline (27.47±12.33 
and 18.47±8.17, W=0.0001, p≤.01). 
Attrition: 
20 did not become totally abstinent 
within the 12 weeks of therapy;  
4 discontinued therapy prematurely; 
3 did not attend the booster 
sessions; 
1 refused the therapy recommended. 
Analysis relates to 82 persons 
remaining: 42 clients in group I and 
40 in group II. 
58 responded to questionnaire: 
Group 1: 27; Group 2: 31 
 
First author and 
year:   
Hughes 2010 
Hughes 2011 
(secondary analysis) 
Aim of study: 
To compare gradual 
cessation vs. abrupt 
cessation vs. minimal 
treatment among 
smokers who wanted 
to quit and preferred 
to quit gradually. 
Study Design : 
Individual 
randomised 
controlled trial. 
Quality score: 
Setting: 
USA (Columbia and 
Florence, SC and 
Albuquerque, NM)  
Participants:  
746 community dwelling 
adults 46% male; 
46 (+/- 13) years old;  
82% white, 10% 
black/African American, 
8% other, 13% classed as 
Hispanic;  
47% married, 38% 
divorced, widowed, 
separated, 16% never 
married;  
9% below high school, 
60% high school, 31% 
Method of allocation: 
Concealed 
Intervention(s): 
Smokers who wished to quit were 
randomised to one of two intervention 
arms or a control arm. The 
intervention arms were (a) gradual 
cessation counselling and nicotine 
lozenges to reduce prior to quitting 
(n=297), (b) abrupt cessation 
counselling (n=299). 
Control: 
Brief advice (n=150) 
Participants in the gradual group were 
asked to set a quit date between 3 and 
5 weeks after the study initiation; 
those in the abrupt and control groups 
were asked to set a quit date between 
Hughes 2010 primary 
outcomes: 
Prolonged and point 
prevalence abstinence (past 7 
days) by self report at each 
follow up time. Reported 
abstinence at 6 months, 
verified by CO sample (<10 
ppm). CO verified reduction in 
smoking levels; self-report for: 
nicotine dependence, disrupted 
pattern of smoking, self-
efficacy for resisting smoking, 
motivation to quit, confidence 
in ability to qui, perceived 
difficulty in quitting, preference 
for quitting method. 
Method of analysis: 
Primary: 
No statistical difference at 6 month 
CO verified prolonged abstinence.  
Odds ratio for gradual vs abrupt = 0.6 
(95% CI: 0.3, 1.2) Smokers in the 
gradual condition were less likely to 
make a quit attempt, defined as ≥ 1 
day of not smoking, than those in the 
abrupt and minimal treatment 
conditions (48% vs 64% vs 60%, 
χ2=15.9, p < .001). In the gradual 
condition, for every week delay to 
quit date increased the probability of 
lapsing by 19% (p<0.001) 
NB The authors noted that the type 
of schedule used (formal schedule, 
giving up ‘easiest’ cigarettes first, 
giving up ‘hardest’ cigarettes first) 
Limitations (author) 
Hughes 2010:  
Lack of power in study; 
Abrupt group may have had 
more traditional 
behavioural support. 
Gradual condition received 
more pre- and fewer post-
cessation calls than the 
abrupt condition but 
overall number was the 
same. Counselling time in 
the gradual condition was 
spent on teaching rather 
than coping mechanisms. 
Longer reduction time. 
Patch instead of lozenge. 
Authors question validity of 
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++ (Hughes 2010) 
External validity 
score: 
+ 
 
college graduate. 
Inclusion: 
≥18-year-old smokers of ≥ 
15 CPD; want to quit 
smoking in the next 30 
days and prefer to quit 
gradually rather than 
abruptly; no change in 
cigarettes/day by ± 20% 
or more in the last month; 
willing to use nicotine 
lozenge; no FDA caution 
for use of lozenge 
requiring physician 
contact. 
Exclusion: 
None provided 
 
Participants wanted to 
quit gradually. 
1 and 3 weeks from the study onset.  
All participants were sent a booklet 
and nicotine lozenges to use starting 
on their pre quit (for the gradual 
group) or quit date (for the abrupt or 
brief advice group) and for up to 12 
weeks post quit date. 
Sample sizes:  
N=746 (297 gradual cessation, 299 
abrupt cessation, 150 minimal 
treatment) 
Baseline comparisons: 
Differences in marital status and 
confidence in quitting – adjusted in 
analysis and did not affect results. 
Hughes 2011: 
1. Time to planned quit date among 
720 participants (97%) who set a 
quit date. 
2. Time to actual quit date (first day of 
abstinence) among the 508 
participants (68%) who made a quit 
attempt. 
3. Among those who made a quit 
attempt (508), whether participants 
quit on or after the planned quit 
date. 
Study power:  
Hughes 2010: not provided only stated 
that lower than expected. Hughes 
2011 did not appear to conduct a 
power calculation. 
Intervention delivery: 
University researchers 
 
 
Baseline characteristics 
compared using χ² tests for 
categorical variables and 
analysis of variance or the 
Kruskal-Wallis test for 
continuous variables. 
Abstinence outcomes and quit 
attempts were analyzed bi-
variately using χ² tests, with 
assessment of possible 
confounding variables and 
interactions performed via 
logistic regression. 
Hughes 2011 primary 
outcomes: 
1. Never making a quit attempt.  
2. Not quitting (≥1 day of 
abstinence) by or on the 
planned quit date. 
3. Probability of early lapse 
(any smoking) within the first 
12 weeks. 
4. Not achieving 7-day point-
prevalent abstinence at 6 
months. 
Method of analysis: 
Secondary analysis of data 
subsets. Logistic regression was 
used to obtain odds ratios for 
dichotomous outcomes. 
Proportional hazards regression 
provided hazard ratios for the 
analysis of probability of an 
early lapse, with time to lapse 
as the survival variable. All 
analyses for the combined 
sample adjusted for 
experimental condition by 
including design variables for 
the conditions as covariates in 
did not make a difference and the 
results were pooled.  
Attrition: 
Response rate 76-79% at six months 
but ITT analysis used and non 
respondents assumed to be smokers. 
Hughes 2011 
1. The relationship between time to 
the planned quit date and never 
making a quit attempt was 
significant for the abrupt condition 
(χ² = 8.9, p = .003) but not for the 
gradual condition (χ² = 3.8, p = .05) 
2. 57% of the gradual group either 
quit after their planned date or did 
not make a quit attempt at all, 
which was somewhat higher than 
those in abrupt (29%) and control 
(33%) groups.  No formal 
comparison between groups was 
made. 
3. The relationship between time to 
planned quit date and the 
probability of lapsing early was 
significant within both the gradual 
(χ² = 4.8, p = .03) and abrupt (χ² = 
5.2, p = .02) conditions. Those who 
quit after their planned quit date 
were more likely to lapse early on 
than those who quit on their quit 
date both within the abrupt (χ² = 
5.7, p = .02) and brief advice (χ² = 
8.0, p = .005) groups. This finding 
was not significant for the gradual 
group. 
4. No relationship was found 
between time to planned quit 
date, time to actual quit date, or 
quitting after versus on quit date 
and 6 month abstinence for any of 
self-reports as approx 50% 
of those reporting 
abstinence did not agree to 
CO test or their test result 
was high. 
Limitations (review team): 
Lack of power calculation. 
Evidence gaps:  
Need for more RCTs of 
gradual v abrupt. 
Hughes 2011 
Limitations (author):  
Identified differences may 
be due to baseline 
differences in motivation in 
those choosing shorter vs 
longer delays till quitting. 
Participants self-selected 
delayed versus immediate 
cessation, rather than being 
randomised. 
Secondary analysis using 
subsets of data from the 
original study. 
Limitations (review team): 
As above. 
Evidence gaps: 
Further replications of 
study findings (delaying a 
quit attempt in smokers 
trying to quit is associated 
with worse outcomes) are 
needed. 
Funding sources both 
papers:   
Grant DA-017825 (JH), 
Senior Scientist Award DA-
00490 (JH) and Institutional 
Training Grant DA-07242 
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the models. Odds ratios and 
hazard ratios quantified the 
increased probability of the 
worse outcome for each 1-
week delay. 
Follow-up periods: 
2 weeks, 4 weeks, 6 weeks, 3 
months, and 6 months after the 
quit date set by the participant 
at study onset. 
  
the intervention groups or for the 
combined sample.  
 
(EP) from the US National 
Institute on Drug Abuse. 
Hughes: Research grants 
from Pfizer; honoraria or 
consulting fees from 
companies that develop, 
sell or promote smoking 
cessation products or 
services including Abbot 
Pharmaceuticals; Acrux; 
Aradigm; EPI-Q, Evotec; 
Exchange Limited; Free and 
Clear; Glaxo-Smith Kline; 
Golin Harris; Healthwise; 
McNeil Pharmaceuticals; 
Novartis Pharmaceuticals; 
Oglivy Health PR, Pfizer 
Pharmaceuticals; Pinney 
Associates; Propagate 
Pharmaceuticals. Xenova.  
All other authors have 
nothing to declare.  
Applicable to UK?  
Yes noting country 
differences 
First author and 
year:   
Jiménez-Ruiz 2009 
Aim of study: 
To examine the 
outcome of a 
programme of 
progressive 
reduction, using 
nicotine gum, as a 
prelude to complete 
cessation among 
current smokers who 
sought treatment in 
Setting: 
Smokers’ Clinic  Madrid, 
Spain 
Participants: 
116 smokers,  
70 (60%) men and 46 
(40%) women; 
Age  45.7 (+/- 12.65) years  
Inclusion: 
Current smokers aged ≥18 
who wanted to quit but 
not abruptly.  
Exclusion: 
None stated 
Method of allocation: 
Uncontrolled study therefore no 
allocation 
Intervention(s): 
The programme comprised two 
phases: 16 weeks of progressive 
reduction preceding complete 
cessation, followed by an abstinence 
phase of 6 months. The reduction 
phase involved eight clinic visits which 
included cognitive behavioural 
therapy. Smokers were instructed to 
use nicotine gum at recommended 
levels based on according to their 
Primary outcomes: 
Continuous abstinence, defined 
as not even a puff, verified by 
an expired CO level of ≥10ppm. 
Secondary outcomes: 
Numbers reducing 
consumption by 50% at week 8. 
Numbers having successfully 
quit by week 16. Also reported 
adverse events. 
Follow-up periods: 
Weeks 8 and 16 after baseline. 
3 and 6 months after the quit 
date. 
Primary: 
Continuous abstinence rates were 
39% at the 6 month follow-up and 
44% at 3 months.  At six months 
differences in abstinence rates within 
subgroups were not significant (48% 
in the group wanting to use 
reduction to quit compared to 32% in 
the refractory group, p=0.8). 
Secondary: 
At the end of week 8 68% achieved 
reduction in consumption of ≥50%.  
By the target quite date 57% 
achieved complete cessation. 
Limitations (author):  
No comparison group. 
Selection bias - outcomes in 
smokers who chose to 
follow a progressive 
reduction programme. All 
smokers received 
psychological and 
pharmacological 
treatments free of charge.  
Limitations (review team): 
As above. 
Evidence gaps: 
None reported. 
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smokers’ clinic but 
who did not want to 
quit abruptly. 
Study Design : 
Uncontrolled before 
and after study 
Quality score: 
- 
External validity 
score: 
- 
 
 
 
Participants wanted to 
quit gradually. 
baseline cigarette consumption in 
week 1, with a target of progressively 
reducing CPD.  By the end of week 8 
the target was a reduction of ≥50%, 
with abstinence by week 16 Smokers 
who had not quit by Week 16 were 
discharged from the programme. 
Two groups of smokers were 
compared: those who went to the 
clinic wanted to quit but not abruptly, 
and refractory smokers, who had failed 
to quit several times and who were 
advised to follow a progressive 
reduction programme. 
Control: 
No control group 
Sample sizes: 
116 participants in total, 50 (43%) 
asking for progressive reduction 
treatment, and 66 (57%) refractory 
smokers  
Baseline comparisons: 
No statistically significant differences 
between the two groups. 
Study power: 
No power calculation provided. 
Intervention delivery: 
Authors based in smokers’ clinic at the 
Institute of Public Health in Madrid. 
Method of analysis: 
Not stated. 
Point prevalence abstinence rate at 
week 16 was higher among smokers 
who had successfully reduced by half 
at week 8 compared with those who 
had failed to reduce by half at week 8 
(75% v. 19%, OR = 3.2, 95% CI = 2.12, 
4.82; p<0.001). 
All smokers who had successfully quit 
at 16 weeks continued to use NRT 
into the abstinence phase but no 
subject used NRT for more than 4 
months post quit date. 
Attrition: 
80 (69%) completed the reduction 
phase and 59 (51%) completed the 
abstinence phase.  Smokers who 
missed a visit or withdrew from the 
study were counted as smokers for 
the analysis, so follow-up data are 
presented for all 116 participants. 
 
Funding sources: 
Department of Health of 
the Government of Madrid, 
Spain. 
CAJ-R consults for 
manufacturers of smoking 
cessation medications. 
Applicable to UK? 
A highly intensive 
programme and Expert 
Advisory Group indicate 
this is not likely to be 
feasible in the UK. 
First author and 
year:   
Marks 2002 
Sykes 2001 
Aim of study: 
To test the effect of a 
self-help cognitive 
behavioural therapy 
programme for 
Setting: 
Community-based 
smoking cessation clinic in 
deprived area of North 
London. 
Participants: 
260 adults (no age data) 
who were recruited  via 
posters and pamphlets in 
Method of allocation: 
Interventions were randomly allocated 
to dates.  When smoker phoned to 
volunteer the receptionist (blinded to 
intervention status) booked them into 
the first available date. 
Intervention(s): 
The QFL programme is an ‘eclectic 
combination’ of 30 cognitive 
Primary outcomes: 
Participants’ self-reported 
point prevalence abstinence at 
six months (post intervention) 
validated by CO. 
Secondary outcomes: 
7-day point prevalence 
abstinence (confirmed by CO 
for 74% of reports); 
Primary: 
Note: 12 month results (Marks 2002) 
relate to 116/131 in the intervention 
group and 104/129 in the control 
group.  
6 month results (Sykes 2001) relate to 
122/131 in the intervention group 
and 107/129 in the control group.  
At 12 months 19.8% [23] (95% CI 
Limitations (author):  
High pre-enrolment drop 
out (88%) suggests that 
participants were highly 
motivated.  Only 25% of 
those who volunteered by 
phone booked in, and only 
50% of those attended the 
first session. 
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smokers ‘Quit for 
Life’ (QFL) in 
comparison with 
control treatment 
‘Stopping Smoking 
Made Easier’ (SSME). 
Study Design : 
Individual quasi-
randomised 
controlled trial 
Quality score: 
+  
External validity 
score: 
++ 
 
GP waiting rooms, 
pharmacies and a library 
notice board; also local 
newspaper story about 
successful quitters. 28% 
from manual occupations; 
14% unemployed; 64% 
female 
Inclusion: 
Participants who phoned 
the clinic to volunteer and 
appeared at the first 
session. 
Exclusion: 
No exclusion criteria. 
 
Participants' motivations 
unknown but had all 
contacted the smoking 
cessation clinic 
behavioural and other relevant 
methods in a self-help package 
consisting of a handbook (also 
provided as a cassette tape with 
relaxing music on the other side), 
reduction cards, a progress chart and 
other necessary materials.  The aims 
are gradual reduction over 7-10 days, 
by offering a choice of psychological 
support methods which guide the 
smoker towards a daily reduction of 
50%. The programme also provides 
relapse prevention support post quit 
date, to three months. 
Control: 
SSME is a pocket sized leaflet 
recommending a staged preparation 
with an abrupt cessation date and 
recommendations to phone the 
national ‘quitline’, GP or health centre 
for further support. 
Sample sizes: 
Eligible: 2080  
Intervention: 131 
Control: 129 
Baseline comparisons: 
Balanced 
Study power: 
No power calculation reported 
Intervention delivery: 
University researchers 
Cigarettes per day ≥25% less 
than baseline for at least 4 
weeks 
Follow-up periods: 
6 months after the intervention 
(not clear if start date or quit 
date) 
Method of analysis: 
Χ2 and % difference with 95% 
CI. 
13.0, 28.3) participants in the in the 
QFL group were abstinent compared 
to 5.8 % [6] (95% CI 2.1, 12.1) in the 
SSME group. P<0.0001  
At 6 months, 17.2 % (95% CI 11.0, 
25.1) participants in the QFL group 
were abstinent compared to 5.6 % 
(2.1, 11.8) in the SSME group. 
P<0.0001 
Secondary: 
11.5% (95% CI 6.4, 18.5) had reduced 
CPD+ by ≥25% compared to 0% 
71.3 % (62.4, 79.1) had made no 
change compared to 94.4% (88.2, 
97.9). 
Abstinence and reduction rates were 
analysed separately for: 
 Male vs female  
 Participants in SES groups I-IIIN 
and IIIM-V and SES groups I vs V.    
There were no statistically significant 
differences (figures not provided). 
Attrition: 
15% at 12 months.  
Limitations (review team): 
No power calculation; CO 
confirmation for 74% of 
reports only. No maximum 
level of CO ppm was 
specified) and it appears 
that those who had 
≥10ppm CO levels were 
considered abstinent. No 
ITT analysis. Authors are 
suppliers of the QFL 
(cognitive behavioural) 
intervention. 
Evidence gaps: 
Further investigation of 
free cognitive behavioural 
therapy combined with free 
NRT in a community 
setting. 
Funding sources: 
Not reported 
Applicable to UK? 
Yes 
First author and 
year:   
Martin 1997  
Aim of study: 
Martin: To evaluate 
the effect of three 
specially adapted 
Setting:  
San Diego, California 
Participants: 
205 community dwelling 
recovering alcoholics ≥18  
M: 113; F 92 
Mean age 41.8  
Method of allocation: 
Not stated 
Intervention(s): 
1. Standard treatment [ST] – modified 
American Lung Assn (ALA 1986) 20-
day quit program, followed by four 
weeks of maintenance counselling 
Primary outcomes: 
Quit status using point-
prevalence rates at 6- and 12-
month follow-ups, and 
continuous abstinence at the 1-
week post-treatment quit 
point. Participants were coded 
Primary: 
Verified mean quit rate at 6  months 
ST = 21% 
BEX = 29% 
BNIC = 27% 
Verified mean quit rate at 12 months 
ST = 26% 
Limitations (author):  
No control group and 
standard treatment has 
been adapted extensively 
to incorporate a 
behavioural support 
component similar to 
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smoking treatment 
and maintenance 
programs in 
recovering alcoholic 
smokers. 
Study Design : 
Quasi-randomised 
trial of three 
interventions (no 
control group) 
Quality score:  
+ 
External validity 
score: 
+ 
 
Ethnicity: 92.7% 
Caucasian 
Mean years of education 
14.6 
Married with partner 30% 
Employed 95% 
Inclusion: 
Report significant 
histories of alcohol abuse 
and dependence with ≥ 3 
months of alcohol and 
drug abstinence.  
Consume average of ≥10 
CPD 
Provide physician 
permission to use nicotine 
gum or undertake 
moderate physical activity 
Exclusion: 
Use of psychotropic 
medications or any 
physical disabilities that 
would hinder engaging in 
a program of moderate 
physical activity. 
 
Participants' motivations 
unknown. 
and of attendance at three Nicotine 
Anonymous (NA) meetings per 
week.  Quit program comprised four 
weekly 60-75 minute group   
sessions covering self-monitoring, 
relaxation, urge control instruction, 
relapse prevention training and quit 
contracts, and three large-scale 
smoking rate reductions by one third 
each week prior to target quit date 
(week 4), in addition to facilitated 
group discussions. Participants were 
instructed to quit smoking at week 4 
and requested to attend Nicotine 
Anonymous meetings 3x per week. 
2. Behavioural counselling plus 
exercise [BEX]. Eight weekly, 60-75 
min sessions, using a more gradual 
reduction schedule and treatment 
delivery adapted for recovering 
alcoholic smokers. Former smoker 
group "mentors" were employed to 
adapt the language and techniques 
of the behavioural interventions and 
group discussions to 12-step 
recovery processes. From week 8, 
moderate aerobic exercise 
prescriptions including on-site 
moderate-to-brisk walking, around 
an outdoor track, and use of 
exercise equipment, progressing 
from 15 to 45 min, and thrice weekly 
home exercise of a similar nature. 
3. Behavioural counselling plus NRT 
[BNIC] Counselling similar to the BEX 
Group was combined with free post-
quit nicotine gum (2mg) throughout 
maintenance. Participants were 
instructed to chew between one and 
six pieces of nicotine gum through 
the day, as prophylaxis or on strong 
as non-smokers if they 
reported not smoking within 
the previous 24 hr (7 days for 1-
week post-treatment measure) 
and had CO levels < 10 ppm. If 
CO data were not available, an 
informant verified that the 
participant was not smoking.  
Participants gave details of two 
informants – one each from 
their home and work 
environments. 
Results report only verified 
smoking status. 
Follow-up periods: 
Post treatment, 6 and 12 
months. 
Method of analysis: 
Chi-square analysis was 
performed at each time point 
on the verified quit status. 
  
BEX = 27%  
BNIC =  27% 
No differences were statistically 
significant at 6 or 12 months 
I week rates also reported. 
Attrition:  
Not reported 
 
treatments for groups 2 
and 3. 
Limitations (review team): 
Three interventions with 
multiple components – no 
control/standard 
treatment. 
Authors only report 
percentage quit rates. They 
go up between 6 and 12 
months in ST group. This is 
not discussed. 
Evidence gaps:  
None reported. 
Funding sources: 
Grant No. 2RT0053 from 
the California Tobacco-
Related Disease Research 
Program. 
Applicable to UK? 
Limitations particularly 
around Nicotine 
Anonymous which has very 
little UK presence. 
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urges. All participants continuing 
nicotine gum use beyond 3 months 
post-quit were systematically faded 
from its use by 6 months post-quit.  
In addition a treatment deposit of $50 
was collected initially from all 
participants. Deposits were returned 
contingent on session attendance and 
completion of homework assignments. 
All three groups received instructions 
to reduce the number of cigarettes 
smoked prior to target quit date. The 
target quit date was week 4 for the TS 
group, and week 8 for the two other 
groups.  
Control: 
No control group  
Sample sizes: 
ST = 70, BEX = 72, BNIC = 63 
Baseline comparisons:  
Significant differences between BNIC 
group and the other two groups in two 
measures: number of years abstinent 
from alcohol and drugs, and 
employment status. The authors do 
not report whether these factors were 
adjusted for in the analyses. 
Study power: 
No power calculation reported 
Intervention delivery: 
ST: Trained, PhD-level, and master's 
level smoking health educators 
BEX: Doctoral- and master's-level 
group co-leaders with ≥1 year of 
experience co-facilitating at least two 
former treatment groups using the 
techniques under supervision. 
BNIC Behavioural counselling similar to 
THR 2.3 Review 2 - Effectiveness of tobacco harm reduction approaches with the intention of quitting, with and without 
assistance 
 
 
53  
 
the BEX Group 
First author and 
year:   
O’Leary Tevyaw 2007 
Aim of study: 
To investigate the 
efficacy and 
feasibility of a 
contingency 
management* (CM) 
protocol for 
adolescent smokers 
that included use of a 
reduction phase.   
*Rewards for 
response 
Study Design : 
Individual partial 
randomised 
controlled trial  
Quality score:  
– 
External validity 
score: 
– 
Setting: 
US high schools in 
Providence RI. 
Participants: 
23 students.  19 analysed 
- 52.6% female, 74% 
white, 21% other, 5% 
native American, age 16.4 
± 1.2 
Inclusion: 
Aged 14-18 with CO 
≥10ppm at baseline.  Did 
not need to be motivated 
to quit.   
Exclusion: 
None stated. 
 
Participants did not need 
to be motivated to quit. 
Method of allocation: 
Randomisation using sealed envelopes 
Intervention(s): 
One week reinforcement for 
attendance to encourage provision of 
CO samples (RA); one week washout 
and one week contingency 
management (CM).  Order of weeks 
was counterbalanced (RA/washout/CM 
and CM/washout/RA).  Vouchers (for 
use at local shopping mall) for CO 
samples based on amount of CO 
reduction (contingency management). 
Participants were also randomised 
during the CM phase to reductions 
followed by abstinence (CM-
reduction).  
Control: 
Participants were randomised in the 
CM phase to reinforcement for 
abstinence only (CM-abstinence). 
Sample sizes: 
N=23 but 2 deemed ineligible after 
enrolling and 2 missed 3+consecutive 
readings and excluded, leaving 19. 
Non random distribution to phase: 
RA/washout/CM: 7 
CM/Washout/RA: 12 
Random distribution to condition: 
CM-reduction: 10 
CM-abstinence: 9 
Baseline comparisons: 
No statistically significant differences - 
very wide confidence intervals 
Study power: 
No power calculation reported 
Intervention delivery: 
Primary outcomes: 
C O readings (≤5ppm denoting 
abstinence).  
Secondary outcomes: 
Follow-up periods: 
Three week intervention 
(randomisation at CM stage in 
third week), with two weeks 
post-intervention follow up. 
Method of analysis: 
% abstinent readings 
 
 
Primary: 
Participants randomised to the CM-
abstinence condition had a similar 
percentage of abstinent readings in 
the CM and RA phases (59% vs 48%).  
Participants in the CM-reduction 
condition tended to have more 
abstinent readings in the CM phase 
than in the RA phase (50% vs 37%). 
Attrition: 
93% attendance at scheduled visits. 
Limitations (author):  
None reported. 
Limitations (review team): 
Very small study with 
complex permutations.  
Analysis on only 19/23 
students. Results could 
have been by chance. 
Evidence gaps: 
Further exploration of the 
effect of introducing 
reinforcement for 
attendance prior to 
administration of 
contingency management. 
Funding sources: 
Not stated 
Applicable to UK? 
Unlikely. US high school 
setting. Large incentive 
payments (subjects could 
earn up to $185) 
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University researchers 
First author and 
year:  
Riley 2002  
Aim of study: 
To modify a smoking 
cessation programme 
that uses 
computerized 
scheduled gradual 
reduction (The 
LifeSign programme) 
for use with 
adolescent smokers 
and to test the 
feasibility of this 
cessation approach in 
group support and 
minimal contact 
modalities. 
Study Design : 
Two uncontrolled 
before and after 
studies 
Quality score: 
- 
External validity 
score: 
- 
 
Setting: 
USA Local area high 
schools in Fairfax County, 
Virginia (different schools 
for each study). 
Participants: 
High school students 
Study 1: 17 students, 47% 
female, 82% Caucasian, 
mean age 16.7 (SD 0.72) 
Study 2: 18 students, 72% 
female, 83% Caucasian, 
mean age 16.1 (SD 0.86) 
Inclusion: 
Self report ≥7 CPD, desire 
to quit smoking, no 
current use of smokeless 
tobacco or NRT 
Exclusion: 
None stated 
Method of allocation: 
Study 1: Volunteers recruited by the 
school Vice-Principal following 30 min 
lunchtime information meeting. 
Study 2:  Response to posters and 
announcements in school. 
Intervention(s): 
Study 1: 7 weekly 30 min support 
meetings by health educator. After 
week 1 computer prompted cigarette 
use on a scheduled gradual reduction 
lasting 10-28 days, depending on initial 
use and on adjustments for difficulties 
following the schedule. 
Study 2:  Computer scheduled 
reduction as per Study 1 but modified 
as per marketing class feedback from 
previous study. No weekly meetings; 
one mid-point contact after 3 weeks. 
Control: 
No control. 
Sample sizes: 
Study 1: 17; Study 2: 18 
Baseline comparisons: 
Not applicable (uncontrolled) 
Study power: 
Not provided 
Intervention delivery: 
Authors are developers computerised 
interventions  or university 
researchers. 
Primary outcomes: 
Both studies:  Self report and 
CO-corroborated (≤10 ppm) 7-
day abstinence. Self reported 
CPD. 
Follow-up periods: 
Study 1:  Post-treatment at 7 
weeks. 
Study 2:  Post-treatment at 7 
weeks and 1 year follow-up 
phone interviews with CO-
validation for those reporting 
abstinence. 
Method of analysis: 
% and CPD (standard 
deviation). 
Primary: 
Study 1:  Post-treatment 5 (29%) 
were 7-day abstinent and 10 (59%) 
had reduced CPD by ≥50%.  Among 
non-quitters an overall self reported 
reduction of CPD from 12.5 (SD 4.6) 
to 7.0 (SD 6.4). 
Study 2:  Post-treatment 3 (17%) 
were 7-day abstinent.  Among non-
quitters there was a 43% self 
reported reduction in CPD from 11.4 
(SD 7.8) to 6.5 (SD 5.8). At 1-year 
follow up, 7 claimed ongoing 
abstinence but only two provided 
samples for CO-verification, reducing 
the validated quit rate to 11%. Mean 
CPD for ongoing smokers was 9 (SD 
4.4); a 2.5 mean CPD increase from 
the post-treatment rate. 
Attrition: 
Study 1:  15/17 (88%) completed 
post-treatment evaluation.  5 
reporting 7-day abstinence were 
corroborated by CO. 
Study 2:   17/18 (94%) completed 
post-treatment evaluation.  3 
reporting 7-day abstinence were 
corroborated by CO. At one year 7 
reported 7-day abstinence but CO 
validation only for 2 subjects (29%). 
 
Limitations (author):  
Small sample sizes severely 
limit generalisability.   
Groups were quite different 
and no direct comparisons 
can be made between the 
two delivery modalities.  No 
control group. 
Limitations (review team): 
Feasibility studies only and 
methodologically very 
weak. 
Authors work for company 
that has commercial 
interests in developing 
computerised smoking 
cessation products. 
Evidence gaps: 
Need for a large scale 
controlled trial with long-
term follow-up. 
Funding sources: 
Partial funding from the 
National Cancer Institute of 
the National Institutes of 
Health.  
Several authors work for a 
company that develops 
computerised smoking 
cessation products. 
Applicable to UK? 
No. Not generalisable 
beyond the very small 
populations studied. 
First author and 
year:  
Setting: 
27 study sites across the 
Method of allocation:  
Self selected for dose of NRT, then 
randomised via computer generated 
Primary outcomes: 
 28 day self-reported 
continuous abstinence, verified 
Primary: 
28 days continuous abstinence for 
NRT vs placebo(95% CI): 
Limitations (author):  
 Lack of information on 
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Shiffman 2009 
Aim of study: 
To test the efficacy of 
nicotine gum in 
facilitating cessation 
through gradual 
reduction. 
Study Design :  
Individual 
randomised 
controlled trial  
Quality score 
++ 
External validity 
score 
+ 
 
USA.  
Participants:  
3297 US smokers 
interested in quitting 
gradually, community-
recruited via print and 
radio advertisements.   
≥18 years.  57% women.  
Circa 97% white, circa 
76%  had some college 
education, income data 
provided (but dates of 
intervention unclear- 
although funding 
commenced pre-2001)  
 
Participants interested in 
quitting gradually. 
randomisation scheme 
Intervention(s): 
NRT gum at 2 mg or 4 mg (as selected 
by patient) plus instruction to extend 
time to first cigarette (using gum) by 
one hour each day. 
Control: 
As above, with placebo gum 
Sample sizes: 
6923 eligible participants screened; of 
whom 3297 enrolled.  
1636 selected 2 mg gum 
1661 selected 4mg gum. 
Allocation: 
2mg active  819 
2mg placebo 817 
4mg active 830 
4 mg placebo 831 
Baseline comparisons: 
Balanced 
Study power: 
No power calculation reported but a 
large study 
Intervention delivery:  
Authors are university researchers and 
pharmaceutical company 
by CO ≤10 ppm.  
Secondary outcomes: 
Reduction in smoking, 
achievement of initial 
abstinence (24 hrs) and 
abstinence at 6 months verified 
by two CO readings, with an 
average of ≤10 ppm. 
Follow-up periods: 
24 hour, 28 day and 6 months 
following first day of 
abstinence during cut-down 
period (up to 8 weeks) 
Cigarettes per day, serum 
thiocyanate, gum use, adverse 
events measured during cut 
down periods.  During weeks 1-
8 42.4% of participants 
reported an adverse event with 
those on active gum more likely 
to report than those on placebo 
(48.2% vs 36.6%; p<0.001).  
Most common events were 
nausea, hiccups and heartburn.  
For gastrointestinal symptoms 
figures for active vs placebo 
gum were26% vs 14.5% 
(p<0.001) and 12% vs 8.6% 
(p=0.002) for respiratory 
symptoms. 
Method of analysis: 
Cochran-Mantel-Haenszel tests 
controlled for study site and 
dose. Odds ratios and 95% CI 
Overall OR =  2.83 (1.10, 3.1) 
2mg OR =  2.0  (1.4, 2.9) 
4mg OR =  4.7 (2.8, 7.7) 
Secondary: 
6 months continuous abstinence for 
NRT vs placebo:  
Overall OR =  2.86 (1.93, 4.24) 
2mg OR =  1.8 (1.1, 2.9) 
4mg OR =  6.0 (2.9, 12.3) 
[Also OR data for 24 hours 
abstinence and smoking reduction at 
2 weeks ] 
Attrition: 
Not possible to calculate 
 
subjects screened out of 
participation (to help 
assess generalisability?) 
 Some groups excluded 
(eg those with 
cardiovascular disease) 
Limitations (review team) 
 Not possible to assess 
attrition 
 Concerns about drug 
company involvement in 
write up. 
Evidence gaps: 
None reported 
Funding sources: 
Funded by SmithKline 
Beecham (now 
GlaxoSmithKline) Consumer 
Healthcare.  One author 
employed by GSK; two are 
consultants to the company 
and one has a financial 
interest in the development 
of new NRT medications. 
Applicable to UK? 
Seems feasible 
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APPENDIX B: SUMMARY OF QUALITY APPRAISAL – INCLUDED STUDIES  Key to headings (brief summary from Appendix F, NICE 2009):  1.1 Source population described; 1.2 Eligible population 
representative of source ; 1.3 Selected population representative of eligible; 2.1 Population described; 2.2 Intervention/comparison described; 2.3 Allocation concealed; 2.4 Blinded; 2.5 Exposure adequate; 2.6 Contamination low; 2.7 
Other interventions similar in groups; 2.8 All participants accounted for; 2.9 Setting reflects UK practice; 2.10 Intervention reflects UK practice; 3.1 Reliable outcomes; 3.2 Complete outcomes; 3.3 Important outcomes assessed; 3.4 
Relevant outcomes; 3.5 Similar follow up times; 3.6 Meaningful follow up; 4.1 Groups similar at baseline; 4.2 ITT used; 4.3 Sufficient power; 4.4 Estimates of effect size given; 4.5 Appropriate analysis; 4.6 Precision; 5.1 Internally valid; 
5.2 Externally valid; ++ Minimal bias; +Bias unclear; - Risk of bias; nr Not reported; na Not applicable 
Author 
Year 
Study 
design 
Population Method of allocation to intervention (or comparison) Outcomes Analyses Summary 
  1.1 1.2 1.3 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 3.1 3.2 3.3 3.4 3.5 3.6 4.1 4.2 4.3 4.4 4.5 4.6 5.1 5.2 
Cinciripini
1994  
Quasi 
RCT 
− + nr + ++ − − + ++ nr ++ + + ++ ++ ++ ++ ++ ++ nr − − ++ + − + + 
Cinciripini 
1995 
Quasi 
RCT 
− nr nr nr ++ nr − ++ ++ ++ nr ++ ++ ++ + ++ ++ ++ ++ + ++ nr ++ ++ + + + 
Etter 
2009 
RCT ++ + ++ ++ ++ ++ − + + + + ++ ++ ++ + ++ ++ ++ ++ + ++ nr ++ ++ ++ + ++ 
Etter 
2011 
RCT ++ + + ++ ++ ++ ++ ++ ++ ++ − ++ ++ − + + ++ ++ − − ++ ++ ++ ++ ++ + + 
Gunther 
1992 
RCT nr nr nr ++ + ++ nr ++ ++ + − + + − − + ++ ++ ++ nr − nr ++ ++ + − + 
Hughes 
2010 
RCT ++ ++ + ++ ++ ++ + ++ ++ ++ + ++ ++ ++ + ++ ++ ++ ++ ++ ++ − ++ ++ ++ ++ + 
Hughes 
2011 
SA ++ + ++ − na − − na na na na ++ ++ + na ++ ++ ++ ++ na − − + ++ + − + 
Jiménez-
Ruiz 2009 
UBA + + + − ++ − − na na na − − + ++ ++ ++ ++ na ++ na ++ nr ++ nr ++ − − 
Marks 
2002 
Quasi 
RCT 
++ ++ + + ++ na + ++ ++ ++ ++ ++ ++ ++ − ++ ++ ++ ++ ++ − nr ++ + ++ + ++ 
Martin 
1997 
Quasi   
RT 
++ ++ + + ++ nr nr ++ ++ ++ − + + + nr ++ ++ ++ ++ + ++ nr ++ ++ + + + 
O’Leary 
Tevyaw 
2007 
Partial 
RCT 
− + − ++ + ++ + + nr ++ ++ + − ++ + ++ ++ ++ − + ++ − − − − − − 
Riley 
2002 
UBA + + na na + na na + na na + − + + + ++ ++ na − na − nr ++ + − − − 
Shiffman 
2009 
RCT ++ + + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + 
RCT =  individual randomised controlled trial  SA = Secondary analysis; UBA = UBA = uncontrolled before and after study; RT = randomised trial, no control group (interventions only) 
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APPENDIX C: EXPERT ADVISORY GROUP  
Dr Julie Bishop Consultant in Public Health and currently Acting Director of Health 
Improvement for Public Health Wales.   
Ms Elen de Lacy Newly appointed Chief Executive of ASH Wales, following a role as Research 
and Policy Manger.   
Dr Keir Lewis  Senior Lecturer at Swansea University and Honorary Respiratory Consultant to 
the Hywel Dda Health Board, Wales, UK.  
Professor Laurence 
Moore 
Professor of Public Health Improvement at Cardiff University, and Director of 
DECIPHer, a UKCRC Centre Public Health Research Excellence 
Ms Helen Poole Secondary care smoking cessation counsellor at the University Hospital of 
Wales.  
Dr Marianne van den 
Bree 
Reader at Cardiff University in the Department of Psychological Medicine and 
Neurology.  
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APPENDIX D:  REVIEW TEAM 
Staff/Resource Description Role 
Ms Ellie Byrne, CISHE, Cardiff 
University 
Study selection 
Dr Ben Carter, North Wales 
Clinical School, Cardiff 
University 
Statistical analysis including meta-analysis and advice 
Mr Andrew Cleves, CEDAR Technical advice 
Ms Fiona Morgan, SURE, Cardiff 
University 
 
Project management, searching, study selection, quality 
assessment, data extraction, narrative synthesis and report 
writing. 
Dr Helen Morgan, SURE, Cardiff 
University 
Searching study selection, quality assessment, data 
extraction  
Ms Ruth Turley, SURE, Cardiff 
University 
Study selection, quality assessment, data extraction 
Dr Alison Weightman, SURE, 
Cardiff University 
Project Director.  Searching, study selection, quality 
assessment, data extraction and report writing. 
Dr Sarah Whitehead, CISHE, 
Cardiff University 
Study selection, quality assessment, data extraction and 
report writing. 
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APPENDIX E:  SEARCH STRATEGY  
The search strategy below was used for effectiveness and barrier/facilitator reviews. It was designed for the 
Ovid MEDLINE(R) database 1966 to August Week 1 2011 and was adapted for use in the other databases 
listed in section 2.1.1. 
1. Smoking Cessation/ or exp Smoking/ 112950  
2. ((Nicotine adj4 (therapy or gum* or inhal* or replace* or lozenge* or tablet* or microtab* or nasal 
spray* or patch* or delivery device* or delivery system* or gel*)) or ((smok* or tobacco or nicotine 
or cigarette*) adj10 NRT)).ti,ab. 3472  
3. 1 and 2 2800  
4. (exp smoking/ or smoking cessation/) and harm reduction/ 156  
5. nicotine/th 2  
6. (Cigarette* adj2 substitut*).ti,ab. 40  
7. ("electronic cigarette*" or e-cigarette* or ecigarette* or ecig* or e-cig* or Intellcig).ti,ab.27  
8. (vaping or (personal adj4 vapori?er)).ti,ab. 3  
9. (Nicotine adj4 (therapy or gum* or inhal* or replace* or lozenge* or tablet* or microtab* or nasal 
spray* or patch* or delivery device* or delivery system* or gel*)).ti,ab. 3465  
10. (Pastille* and (smok* or tobacco or nicotine or cigarette*)).ti,ab. 0  
11. (Nicorette or Nicotinell or Niconil or NiQuitin or Polacrilex or Habitrol or Nicabate or NicoDerm or 
Nicotex or Nicotrol or ProStep or Quickmist).ti,ab. 195  
12. ((Stoppers or Commit or pharmacotherap*) adj3 (smok* or tobacco or nicotine or cigarette*)).ti,ab. 
372  
13. (Stubit or super-25).ti,ab. 0 
14. (pharmacotherapy/ or drug therapy/) and (smok* or tobacco or nicotine or cigarette*).ti,ab. 198  
15. (((pre-quit or prequit or "Stop/start" or abstain* or abstinence or reduc* or declin* or quit* or 
stop* or cess* or cease* or cut down or giv* up) adj4 (smok* or tobacco or cigarette*)) and 
nicotine).ti,ab. 5085  
16. or/3-15 6746  
17. *counseling/ or *directive counseling/ or behavior therapy/ or cognitive therapy/ or Self help 
groups/ 50185  
18. (advis* or advic* or counsel* or help line* or helpline* or self help or selfhelp or ((behavio?r* or 
group or cognitive) adj (support or therap*))).ti,ab. 128768  
19.  (((mobile or cell*) adj (phone*1 or telephone*1)) or (SMS or short message service or text messag* 
or instant messag* or videomessag* or video messag* or multimedia messag* or web or internet 
or computer* or e-mail* or email* or electronic mail* or mailing list*)).ti,ab. 239196 
20. *internet/ or *cellular phone/ or *User-computer interface/ or Therapy, Computer-assisted/mt 
33263  
21. or/17-20 408269   
22. smoking cessation/ or ((pre-quit or prequit or "Stop/start" or abstain* or abstinence or reduc* or 
declin* or quit* or stop* or cess* or cease* or cut down or giv* up) adj4 (smok* or tobacco or 
cigarette*)).ti,ab. 29968  
23. 21 and 22 5821  
24. 16 or 23 10954  
25. randomized controlled trial.pt. 313813  
26. controlled clinical trial.pt. 83155  
27. clinical trial.pt. 466468  
28. trial.ti,ab. 272946  
29. randomi?ed.ti,ab. 279552  
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30. Random allocation/ or ((randomly adj1 (allocat$ or assign$)) or placebo-controlled or placebo 
group).ti,ab. 185061  
31. "controlled before and after".ti,ab. 331  
32. (time adj series).ti,ab. 10470  
33. quasi-experiment*.ti,ab. 3683  
34. Control groups/ or Evaluation studies as topic/ or ((evaluation or intervention) adj3 (control group 
or controlled or study or program* or comparison or "before and after" or comparative)).ti,ab. 
164284  
35. (pre test or pretest or pre-intervention or post-intervention or posttest or post test).ti,ab. 14740  
36. ((systematic* adj1 review) or meta analys*).ti,ab. or meta-analysis/ 60586  
37. "mixed methods".ti,ab. 999  
38. or/25-37 1034277  
39. 24 and 38 3685  
40. (interviews or interview or interviewed or qualitative or ethnograph* or thematic analysis or 
grounded theory).ti,ab. 233563  
41. ((perception* or perceive* or attitude* or view*1 or viewpoint* or standpoint* or encounter* or 
experience* or story or stories or narrative*1 or description* or theme* or opinion* or need*1) 
adj3 (survey* or questionnaire*)).ti,ab. 12123  
42. ((field or case) adj (stud* or research)).ti,ab. 46844  
43. Focus groups/ or Qualitative research/ or Interviews as topic/ or Questionnaires/ or Interview, 
Psychological/ or ((focus or discussion) adj group*1).ti,ab. 293785  
44. process evaluation/ or process evaluation.ti,ab. 871  
45. or/40-44 509964  
46. 24 and 45 2094  
47. 39 or 46 5125  
48. animal/ not (animal/ and human/) 3568174  
49. 47 not 48 5112  
50. (letter or editorial or historical article).pt. 1269683  
51. 49 not 50 5082  
52. limit 51 to (english language and yr="1990 - Current") 4468  
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APPENDIX G: EXCLUDED STUDIES WITH REASONS FOR EXCLUSION 
Reference Reason for exclusion 
Adelman, W.P., Duggan, A.K., Hauptman, P., & Joffe, A. 2001. 
Effectiveness of a high school smoking cessation program. 
Pediatrics, 107, (4)  
Smoking cessation study with 
no gradual reduction element. 
Ames, S.C., Patten, C.A., Offord, K.P., Pennebaker, J.W., 
Croghan, I.T., Tri, D.M., Stevens, S.R., & Hurt, R.D. 2005. 
Expressive writing intervention for young adult cigarette 
smokers. Journal of Clinical Psychology, 61, (12) 1555-1570  
Smoking cessation study with 
no gradual reduction element. 
Aryanpour, M., Tarahomi, M., Heydari, G.R., Hesami, Z., 
Ramezankhani, A. 2009. The relation between exhaled carbon 
monoxide level and smoking cessation outcome. Tanaffos, 8, 
(3) 10-16 
Smoking cessation study with 
no gradual reduction element. 
Ashton, M., Miller, C.L., Bowden, J.A., Bertossa, S. 2010. 
People with mental illness can tackle tobacco. Australian and 
New Zealand Journal of Psychiatry, 44, (11) 1021-1028  
Study includes some who 
wanted to cut down to quit, but 
data on reduction only. 
To Review 3  
Audrain-McGovern, J., Stevens, S., Murray, P.J., Kinsman, S., 
Zuckoff, A., Pletcher, J., Moss, D., Baumritter, A., Kalkhuis-
Beam, S., Carlson, E., Rodriguez, D., Wileyto, E.P. 2011. The 
efficacy of motivational interviewing versus brief advice for 
adolescent smoking behavior change. Pediatrics, 128, (1) 
e101-e111 
Smoking cessation and 
reduction but no cut down to 
quit. 
To Review 3 
Baker, A., Richmond, R., Haile, M., Lewin, T.J., Carr, V.J., 
Taylor, R.L., Jansons, S., Wilhelm, K., 2006. A randomized 
controlled trial of a smoking cessation intervention among 
people with a psychotic disorder. American Journal of 
Psychiatry, 163, (11) 1934-1942 
Smoking cessation and 
reduction but no cut down to 
quit. 
To Review 3 
Baker, A., Richmond, R., Lewin, T.J., Kay-Lambkin, F., Baker, 
A., Richmond, R., Lewin, T.J., Kay-Lambkin, F. 2010. Cigarette 
smoking and psychosis: naturalistic follow up 4 years after an 
intervention trial. Australian & New Zealand Journal of 
Psychiatry, 44, (4) 342-350 
Smoking cessation and 
reduction but no cut down to 
quit. 
To Review 3 
Beard E et al. (2011) Association between use of nicotine 
replacement therapy for harm reduction and smoking 
cessation: a prospective study of English smokers. Tobacco 
Control (2011). e-pub ahead of print 1 Dec 2011. 
doi:10.1136/tobaccocontrol-2011-050007 
Study design: observational 
study.  
To Review 4 
Brown, R.A., Ramsey, S.E., Strong, D.R., Myers, M.G., Kahler, 
C.W., Lejuez, C.W., Niaura, R., Pallonen, U.E., Kazura, A.N., 
Goldstein, M.G., Abrams, D.B. 2003. Effects of motivational 
interviewing on smoking cessation in adolescents with 
psychiatric disorders. Tobacco Control, 12 Suppl 4, IV3-10 
Smoking cessation study with 
no gradual reduction element.  
Study data captured in 
Appendix H at the request of 
NICE since information 
provided on a vulnerable group 
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(those with mental illness) 
though the study does not 
meet the inclusion criteria for 
this review. 
Bullen, C., Whittaker, R., Walker, N., Wallace-Bell, M. 2006. 
Pre-quitting nicotine replacement therapy: findings from a 
pilot study. Tobacco Induced Diseases, 3, (2) 35-40 
Smoking cessation study with 
no gradual reduction element. 
Chalmers, K., Bramadat, I.J., Cantin, B., Murnaghan, D., 
Shuttleworth, E., Scott-Findlay, S., Tataryn, D. 2001. A 
smoking reduction and cessation program with registered 
nurses: findings and implications for community health 
nursing. Journal of Community Health Nursing, 18, (2) 115-
134 
Only potentially relevant data 
are available in a figure and 
could not be extracted. 
Attempts to contact the 
authors were unsuccessful. 
Chou, K.R., Chen, R., Lee, J.F., Ku, C.H., Lu, R.B., Chou, K.R., 
Chen, R., Lee, J.F., Ku, C.H., & Lu, R.B. 2004. The effectiveness 
of nicotine-patch therapy for smoking cessation in patients 
with schizophrenia. International Journal of Nursing Studies, 
41, (3) 321-330 
Smoking cessation study with 
no gradual reduction element. 
Cropsey, K.L., Jackson, D.O., Hale, G.J., Carpenter, M.J., 
Stitzer, M.L., Cropsey, K.L., Jackson, D.O., Hale, G.J., 
Carpenter, M.J., & Stitzer, M.L. 2011. Impact of self-initiated 
pre-quit smoking reduction on cessation rates: results of a 
clinical trial of smoking cessation among female prisoners. 
Addictive Behaviors, 36, (1-2) 73-78 
Secondary analysis of subset of 
a smoking cessation study; the 
control group (intervention 
delayed for 6 months). 
Considers self selected 
reduction vs not reducing or 
increasing during the six 
months before receiving the 
intervention, on subsequent 
abstinence. 
Study data captured in 
Appendix H at the request of 
NICE since information 
provided on a vulnerable group 
(female prisoners) though the 
study does not meet the 
inclusion criteria for this 
review. 
Eliasson, B., Hjalmarson, A., Kruse, E., Landfeldt, B., Westin, A. 
2001. Effects of smoking reduction and cessation on 
cardiovascular risk factors. Nicotine & Tobacco Research (3) 
249-255 
Does not measure the effects 
of gradual reduction on 
cessation rates.  Those that 
were not abstinent at the end 
of the intervention were 
removed from the analysis. 
Etter, J.F., Laszlo E. 2007. Postintervention effect of nicotine 
replacement therapy for smoking reduction: a randomized 
trial with a 5-year follow-up. Journal of Clinical 
Psychopharmacology  27 (2) 151-5. 
Long term reduction, not cut 
down to quit. 
To Review 3. 
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Fornai, E., Desideri, M., Pistelli, F., Carrozzi, L., Puntoni, R., 
Avino, S., Gustavsson, G., Sawe, U., Viegi, G., Giuntini, C. 2001. 
Smoking reduction in smokers compliant to a smoking 
cessation trial with nicotine patch. Monaldi Archives for Chest 
Disease, 56, (1) 5-10 
Smoking cessation study with 
no gradual reduction element. 
Glasgow, R.E., Gaglio, B., Estabrooks, P.A., Marcus, A.C., 
Ritzwoller, D.P., Smith, T.L., Levinson, A.H., Sukhanova, A., 
O'Donnell, C., Ferro, E.F., France, E.K. 2009. Long-term results 
of a smoking reduction program. Medical Care, 47, (1) 115-
120 
Smoking reduction study.  
Eligible participants were not 
interested in quitting.  
To Review 3. 
Gulliver, S.B., Kamholz, B.W., Helstrom, A.W., Morissette, 
S.B., Kahler, C.W. 2008. A Preliminary Evaluation of Adjuncts 
to Motivational Interviewing for Psychiatrically Complex 
Smokers. Journal of Dual Diagnosis, 4, (4) 394-413  
Smoking reduction not cut 
down to quit study. 
To Review 3. 
Hovell, M.F., Zakarian, J.M., Matt, G.E., Liles, S., Jones, J.A., 
Hofstetter, C.R., Larson, S.N., Benowitz, N.L. 2009. Counseling 
to reduce children's secondhand smoke exposure and help 
parents quit smoking: a controlled trial. Nicotine & Tobacco 
Research, 11, (12) 1383-1394 
Smoking cessation study with 
no gradual reduction element. 
Hughes, J., Lindgren, P., Connett, J., Nides, M., Lung, H.S. 
2004. Smoking reduction in the Lung Health Study. Nicotine & 
Tobacco Research, 6, (2) 275-280 
Secondary analysis of a 
smoking cessation study.   
Study data captured in 
Appendix H at the request of 
NICE since information 
provided on a large population 
(Lung Health Study) though the 
primary study does not meet 
the inclusion criteria for this 
review. 
Hughes, J.R., Cummings, K.M., Hyland, A. 1999. Ability of 
smokers to reduce their smoking and its association with 
future smoking cessation. Addiction, 94, (1) 109-114 
Secondary analysis of a 
smoking cessation study.   
Study data captured in 
Appendix H at the request of 
NICE since information 
provided on a large population 
(COMMIT study) though the 
primary study does not meet 
the inclusion criteria for this 
review. 
Hurt, R.D., Croghan, G.A., Beede, S.D., Wolter, T.D., Croghan, 
I.T., Patten, C.A. 2000. Nicotine patch therapy in 101 
adolescent smokers: efficacy, withdrawal symptom relief, and 
carbon monoxide and plasma cotinine levels. Archives of 
Pediatrics & Adolescent Medicine, 154, (1) 31-37 
Smoking cessation study with 
no gradual reduction element. 
Ingersoll, K.S., Cropsey, K.L., Heckman, C.J. 2009. A test of 
motivational plus nicotine replacement interventions for HIV 
Reduction but not cut down to 
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positive smokers. AIDS & Behavior, 13, (3) 545-554 quit. 
To Review 3. 
Jolicoeur, D.G., Richter, K.P., Ahluwalia, J.S., Mosier, M.C., 
Resnicow, K. 2003. Smoking cessation, smoking reduction, 
and delayed quitting among smokers given nicotine patches 
and a self-help pamphlet. Substance Abuse, 24, (2) 101-106  
Reduction and cessation but 
not cut down to quit. 
To Review 3. 
Kilburn, K.H., Warshaw, R.H. 1990. Effects of individually 
motivating smoking cessation in male blue collar workers. 
American Journal of Public Health, 80, (Nov 90) 1334-1337  
Smoking cessation study with 
no gradual reduction element. 
Kralikova, E., Kozak, J.T., Rasmussen, T., Gustavsson, G., Le 
Houezec, J. 2009. Smoking cessation or reduction with 
nicotine replacement therapy: a placebo-controlled double 
blind trial with nicotine gum and inhaler. BMC Public Health, 
9, 433 
Reduction and cessation but 
not cut down to quit. 
To Review 3. 
Ma, G.X., Fang, C., Shive, S.E., Su, X., Toubbeh, J.I., Miller, S., & 
Tan, Y. 2005. A culturally enhanced smoking cessation study 
among Chinese and Korean smokers. International Electronic 
Journal of Health Education, 8, 1-10  
Smoking cessation study with 
no gradual reduction element. 
May, R., Tofler, G.H., Bartrop, R., Heinrich, P., Baird, J., 
Jozefiak, E., & de Burgh, S. 2010. Smoking cessation through a 
novel behavior modification technique. American Journal of 
Cardiology, 106, (1) 44-46  
Smoking cessation study with 
no gradual reduction element. 
Nollen, N., Ahluwalia, J.S., Mayo, M.S., Richter, K., Choi, W.S., 
Okuyemi, K.S., Resnicow, K. 2007. A randomized trial of 
targeted educational materials for smoking cessation in 
African Americans using transdermal nicotine. Health 
Education & Behavior, 34, (6) 911-927 
Smoking cessation study with 
no gradual reduction element. 
Okuyemi, K.S., Thomas, J.L., Warren, J., Guo, H., Ahluwalia, 
J.S. 2010. Relationship between smoking reduction and 
cessation among light smokers. Nicotine & Tobacco Research, 
12, (10) 1005-1010 
Secondary analysis of 
retrospectively gathered data 
on reduction in year prior to 
study enrolment. Information is 
not related to the groups into 
which each participant was 
subsequently randomised. 
Owen, L. 2000. Impact of a telephone helpline for smokers 
who called during a mass media campaign. Tobacco Control, 
9, (2) 148-154 
Smoking cessation study with 
no gradual reduction element. 
Patten, C.A., Martin, J.E., Calfas, K.J., Brown, S.A., Schroeder, 
D.R. Effect of three smoking cessation treatments on nicotine 
withdrawal in 141 abstinent alcoholic smokers. Addictive 
Behaviors, 25, (2) 301-306 
Sub-group analysis from later 
cohorts of Martin 1997 (an 
included study). No useable 
supplementary data since data 
are only available for approx 
60% of group.  
Poole, H. Pre-quit in practice: a No Smoking Day initiative. 
Presentation to National Smoking Cessation Conference. 
Explorative observational 
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Glasgow June 2010. Available at 
http://www.uknscc.org/2010_UKNSCC/speakers/helen_poole.html 
[Accessed 24 October 2011]  
rather than intervention study. 
Rose, J.E., Behm, F.M., Drgon, T., Johnson, C., Uhl, G.R. 2010. 
Personalized smoking cessation: interactions between 
nicotine dose, dependence and quit-success genotype score. 
Molecular Medicine, 16, (7-8) 247-253 
Smoking cessation study with 
no gradual reduction element. 
Royce, J.M., Ashford, A., Resnicow, K., Freeman, H.P., Caesar, 
A.A., Orlandi, M.A. 1995. Physician- and nurse-assisted 
smoking cessation in Harlem. Journal of the National Medical 
Association, 87, (4) 291-300 
Smoking cessation study with 
no gradual reduction element. 
Schuurmans, M.M., Diacon, A.H., van, B., X, Bolliger, C.T. 
2004. Effect of pre-treatment with nicotine patch on 
withdrawal symptoms and abstinence rates in smokers 
subsequently quitting with the nicotine patch: a randomized 
controlled trial. Addiction, 99, (5) 634-640 
Smoking cessation study with 
no gradual reduction element. 
Shoptaw, S., Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, 
D., Jarvik, M.E., Rawson, R.A., Ling, W. 2002. Smoking 
cessation in methadone maintenance. Addiction, 97, (10) 
1317-1328 
Smoking cessation study with 
no gradual reduction element. 
Stewart, M.J., Kushner, K.E., Greaves, L., Letourneau, N., 
Spitzer, D., Boscoe, M., Stewart, M.J., Kushner, K.E., Greaves, 
L., Letourneau, N., Spitzer, D., & Boscoe, M. 2010. Impacts of 
a support intervention for low-income women who smoke. 
Social Science & Medicine, 71, (11) 1901-1909 
Smoking cessation study with 
no gradual reduction element. 
Sun, H.Q., Guo, S., Chen, D.F., Jiang, Z.N., Liu, Y., Di, X.L., Yang, 
F.D., Zhang, X.Y., Kosten, T.R., Lu, L. 2009. Family support and 
employment as predictors of smoking cessation success: a 
randomized, double-blind, placebo-controlled trial of nicotine 
sublingual tablets in chinese smokers. American Journal of 
Drug & Alcohol Abuse , 35, (3) 183-188 
Smoking cessation study with 
no gradual reduction element. 
Wennike, P., Danielsson, T., Landfeldt, B., Westin, A., 
Tonnesen, P. 2003. Smoking reduction promotes smoking 
cessation: results from a double blind, randomized, placebo-
controlled trial of nicotine gum with 2-year follow-up.  
Addiction, 98, (10) 1395-1402 
Smoking reduction study which 
did not require participants to 
quit. 
To Review 3. 
Wojtyna, E.J. & Dosiak, M.M. 2009. Cognitive-behaviour 
therapy to enhancing self-esteem concerns improves smoking 
cessation outcome in patients with mental disorders: The 
pilot study. European Psychiatry, 24(Suppl 1) S709 
Conference abstract only – no 
subsequent publication.  
Appears to be a cessation study 
with reduction outcomes but 
no data provided. 
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APPENDIX H: ADDITIONAL STUDIES  
The following studies were identified during study selection. They have data that are potentially of interest and are included at the request of NICE. However, they were 
developed as smoking cessation studies not as cut down to quit studies, and therefore do not meet the review’s inclusion criteria. As these studies are not part of the 
review, they have not been quality assessed.  However, as three of the four studies are secondary analyses, they have significant potential for bias and would have been 
given a quality rating of - (minus).  
First author and year:   
Brown 2003 
Aim of study: 
To test the hypothesis 
that among adolescent 
smokers hospitalised 
for psychiatric and 
substance use 
disorders, motivational 
interviewing (MI) 
would lead to longer 
and more quit 
attempts, reduced 
smoking, and more 
abstinence from 
smoking over a 12 
month follow up. 
Study Design : 
Non-randomised 
controlled study. 
 
Setting: 
Private, university-affiliated 
psychiatric hospital in Rhode 
Island, USA 
Participants: 
Consecutive sample of 191 
adolescents admitted for 
psychiatric hospitalisation. 
Inclusion: 
Age 13-17 years, smoking ≥1 
cigarettes per week for past 4 
weeks; access to a telephone. 
Exclusion: 
Meeting DSM-IV criteria for 
current psychotic disorder.  
Also recent violent behaviour, 
current participation in another 
study, uncertain guardianship 
status, having a sibling in the 
study, language incompatibility, 
living too far away, cognitive or 
hearing impairment. 
Method of allocation: 
In cohorts to avoid potential 
contamination -  planned 
randomisation of cohorts but 
recruitment ended before 
completion 
Intervention(s): 
MI in two 45-minute 
therapist delivered individual 
sessions, if possible during 
hospital stay, plus 6 brief 
monthly telephone sessions 
post discharge for 
participants and 4 for their 
parents. 
Control: 
Brief advice (BA): 5-10 
minutes of advice and 
information on how to quit 
smoking; The "I Quit!" self 
help pamphlet. 
Smoking was banned in 
hospital and 26% participants 
elected to use NRT as in-
patients.  Participants in both 
conditions with quit 
intentions were offered 8-
weeks transdermal nicotine 
patch upon hospital 
discharge.  All were paid in 
gift certificates for their 
participation. 
Primary outcomes: 
7-day point prevalent abstinence, 
quit attempts, changes in 
smoking rate (monthly average) 
and longest quit attempt. 
Reported abstinence verified by 
salivary cotinine (≤15 ng/ml) and 
CO (<10 ppm) at 1, 6 and 12 
month visits. 
Secondary outcomes: 
Proximal outcomes were intent 
to change smoking behaviour on 
discharge and self efficacy for 
smoking cessation. 
Follow-up periods: 
1, 3, 6, 9, 12 months 
Method of analysis: 
х² for abstinence comparison.   
To examine frequency and length 
of longest quit attempt - 
Hierarchical linear modelling and 
generalised estimating equation 
(GEE).  Baseline measures as 
covariates. 
Primary: 
At 12 months follow up 7-day point 
prevalent abstinence was: 
MI 14.0% 
BA 9.9% 
At 6 months % were: 
MI 13.3% 
BA 8.5% 
All p>0.30. 
Across the whole follow up period 
the odds of abstinence was not 
significantly associated with receiving 
motivational interviewing compared 
to brief advice:  OR=1.16 (p=0.68). 
Secondary: 
MI increased self efficacy compared 
to BA and appeared more effective 
for adolescents with little/no 
intention to change smoking but less 
so for those with pre-existing 
intention to cut down or quit.  All 
effects were modest. 
Attrition: 
Not reported although authors state 
that rates of missing data were not 
significantly different between 
groups.  Of 369 patients meeting 
inclusion criteria 147 refused to 
participate. 
 
Limitations (author):  
High participant refusal rate 
(147/369 = 39.8%).  Could 
not generalise outside 
adolescent participants 
with psychiatric/substance 
use disorders. 
Limitations (review team): 
Study designed as a 
cessation intervention and 
not cut down to quit.   
Large number of exclusions 
which may limit 
generalisability.  No 
baseline data.  No attrition 
or power calculation 
reported.  
Evidence gaps: 
Further exploration of 
participant self efficacy and 
intentions in relation to the 
potential effectiveness of 
MI. 
Funding sources: 
Not reported 
Applicable to UK? 
Marginal, though MI and 
BA interventions both 
feasible.  Private hospital 
setting and participants 
were paid. 
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Sample sizes: 
Screened: 1099 
Eligible: 369 
Intervention - 116 
Control - 75 
Baseline comparisons: 
No data provided though 
authors reported no 
significant differences. 
Study power: 
No power calculation 
reported 
Intervention delivery: 
Authors were university 
researchers, some with 
hospital affiliations. 
First author and year:   
Cropsey 2011 
Aim of study: 
To measure differences 
in cessation success 
based on smokers’ self-
initiated pre-quit 
reductions in cigarettes 
per day. 
Study design : 
Secondary analysis of 
data from a 
randomised controlled 
trial. 
Primary study report: 
Cropsey K, Eldridge G, 
Weaver M, Villalobos 
G, Stitzer M, Best A. 
2009.  Smoking 
cessation intervention 
for female prisoners: 
addressing an urgent 
Setting: 
Medium-maximum security 
prison in the South Eastern USA  
Participants (Original study) 
539 female prisoners (250 
intervention; 289 control)  
For this analysis: 
179 women from the original 
study control group which had 
been waitlisted for 6 months, 
prior to receiving an NRT 
(nicotine patches) and 
behavioural therapy smoking 
cessation intervention. 
Reduction group:  43% white, 
46% black; 34% less than high 
school, 41% high schools, 26% 
some college education, mean 
age 33.1. 
No reduction group:  48% 
white, 50% black; 28% less than 
high school, 41% high school, 
Method of allocation: 
Secondary analysis of 
participants who self-selected 
to reduce smoking or retain/ 
increase smoking rates pre- 
cessation intervention. 
Intervention(s): 
Following 6 month wait-list, 
10 week NRT and behavioural 
intervention, Mood 
Management Training to 
Prevent Smoking Relapse, 
modified for correctional 
setting. 
Control: 
N/A 
Sample sizes: 
Reduction: 77 
No reduction: 102 
Baseline comparisons: 
No significant differences 
other than reduction group 
Primary outcomes: 
Self reported CPD and seven day 
point prevalence abstinence 
confirmed by CO (≤2 ppm). 
Follow-up periods: 
10 weekly visits during 
intervention plus 3, 6 and 12 
months post intervention. 
Method of analysis: 
Between-group comparisons 
were carried out using Χ² and 
ANOVA analyses.  Generalised 
Estimating Equation (GEE) to 
estimate long term impact of pre-
quit cigarette reduction. 
 
 
Primary: 
Smokers who showed no pre-quit 
reduction had significantly lower quit 
rates early in cessation treatment 
compared to those who had reduced 
prior to quitting, although the 
differences between the groups were 
not maintained either at the end of 
treatment or during the follow up 
points. Χ2 (GEE) for reduction group 
across time = 28.29 (p=0.003). 
12 months: 13% reduction group; 
11% no reduction group. 
6 months: 13% reduction group; 14% 
no reduction group. [Results provided 
by author] 
Attrition: 
Not applicable. Post hoc analysis of 
completers. Though 20% of the 
screened group did not sign consent 
and 30% of the randomized group 
did not start the intervention. 
Limitations (author):  
Lack of a scheduled 
reduction condition so not 
applicable to interventions 
where subjects are 
instructed to reduce; Self 
initiated smoking reduction 
may serve as a motivational 
marker although no 
baseline state of change 
measure difference. 
Limitations (review team): 
Secondary (post hoc) 
analysis of a cessation 
study; Cutting down to quit 
was not intervention aim. 
Evidence gaps: 
Study specifically designed 
to explore pre-quit 
reduction. 
Funding sources: 
National Institutes of 
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public health need. 
American Journal of 
Public Health 98(10) pp 
1894-901. 
 
31% some college education, 
mean age 33.2. 
Inclusion: 
Aged 18+, smoking ≥5 CPD, in 
general prison population (not 
isolation) and with a desire to 
quit. 
Exclusion: 
Allergy to nicotine, less than 
one year left of sentence, non-
English speaking, serious 
mental illness, mental 
retardation or cognitive 
impairment that would limit 
ability to consent. 
had higher CPD (18.5 vs 14.9, 
p 0.01) 
Study power: 
Not provided 
Intervention delivery: 
Authors are university 
researchers 
Health/National Institute 
on Drug Abuse. 
Applicable to UK? 
Likely - with similar prison 
populations. 
First author and year:   
Hughes 1999 
Aim of study: 
To examine whether 
cigarette smokers in 
the United States can 
significantly reduce 
their smoking and 
retain this reduction 
and, if so, whether this 
predicts an increase or 
decrease in the 
probability of smoking 
cessation in the future. 
Study Design : 
A secondary analysis of 
the COMMIT trial, a 
cluster randomised 
trial.  
Primary study: 
Commit Research 
Group. Community 
Intervention Trial for 
Setting: 
 22 US cities (11 matched pairs) 
of the Community Intervention 
Trial for Smoking Cessation 
(COMMIT). 
Participants: 
1410 subjects from the 
COMMIT trial who smoked at 
both baseline and 2-year follow 
up. 
Average age 42, 53% female, 
20% non-white, 58% with 
college education.  Average 
consumption of 25 cigarettes 
per day at baseline. 
 
Method of allocation: 
Not relevant – secondary 
analysis of a post-cessation 
study cohort. 
Intervention(s): 
 
Control: 
 
Sample sizes: 
1410 ongoing smokers 
 
Baseline comparisons: 
 
Study power: 
 
Intervention delivery: 
Authors were university 
researchers 
Primary outcomes: 
Self-reported cigarettes per day 
and abstinence measured via 
random digit telephone survey of 
ca 5400 households in each of 
the 11 COMMIT communities. 
Secondary outcomes: 
 
Follow-up periods: 
2 and 4 years. 
Method of analysis: 
Odds ratios (95% Confidence 
Intervals); Linear regression 
analysis for exploration of 
reduction/quitting behaviours 
over time. 
Primary: 
Smoking reduction neither promotes 
nor undermines cessation.   
 
The odds ratio for successful 
cessation at 4 years for those who 
had reduced smoking by ≥50% at two 
years compared to those who had 
increased their smoking by ≥ 5% at 
two years was not significant at 1.72 
(0.85, 3.46). 
 
Among the 40% of participants who 
had reduced their smoking by ≥5% at 
2 years, 52% reported the same or 
greater reduction at 4 year follow up. 
 
Secondary: 
 
Attrition: 
34% loss to follow up by 4 years. 
 
Limitations (author):  
Lack of biochemical 
verification of cessation. 
 
Limitations (review team): 
Self reported results only. 
Secondary analysis of a 
smoking cessation trial that 
did not promote smoking 
reduction as a goal. 
 
Evidence gaps: 
 
Funding sources: 
 
Applicable to UK? 
COMMIT was a huge US 
community-based study.  
May be generalisable to the 
UK. 
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Smoking Cessation 
(COMMIT): Summary 
of design and 
intervention. Journal of 
the National Cancer 
Institute 1991; 
83(22):1620-8. 
  
First author and year:   
Hughes 2004 
 
Aim of study: 
To examine the ability 
of smokers who failed 
to quit smoking in the 
Lung Health Study to 
reduce the number of 
cigarettes per day and 
maintain this reduction 
and whether reduction 
predicted increased or 
decreased future 
cessation. 
Study Design : 
Secondary analysis of a 
smoking cessation RCT 
(counselling and 
nicotine gum) 
 
Setting: 
Multiple recruitment methods 
from centres in the USA. 
 
Participants: 
1,722 (of 3,923) participants 
with early lung disease who 
enrolled in the Lung Health 
Study and were still smoking at 
first year follow up. 
  
Inclusion: 
Aged 35-60 years; Smoked at 
least 10 CPD on at least 1 of 30 
days prior to screening; had 
mild obstructive lung disease 
 
Exclusion: 
Serious health condition that 
would affect the lungs or 
interfere with participation. 
Method of allocation: 
Not relevant – secondary 
analysis 
Intervention(s): 
Smoking cessation (10 weeks 
cognitive behavioural 
counselling and nicotine gum) 
plus active bronchodilator;  
Smoking cessation plus 
placebo. 
Beyond intervention, clinic 
visits each four months for 
counselling. 
 
Control: 
Usual care (no intervention) 
 
Sample sizes: 
 
Baseline comparisons: 
 
Study power: 
 
Intervention delivery: 
 
Primary outcomes: 
CPD and point prevalent (no time 
period - check?) abstinence.  
Abstinence verified by salivary 
cotinine and CO at annual visits. 
Follow-up periods: 
Annually from 1-5 years. 
Method of analysis: 
х
2 
for categorical variables (incl. 
abstinence), t statistics for 
quantitative variables.  Logistic 
regression to explore the effect 
of reduction and other co-
variates on quit attempts and 
long term abstinence. 
NB Bronchodilator had no effect 
and the two intervention groups 
were combined. 
Primary: 
Reduction can be maintained but 
neither predicts an increased nor 
decreased probability of future 
cessation. 
Of subjects who did not reduce 
smoking at year 1, 6% had quit at 
year 2 and 3% by year 5. 
Figures for quit rates at years 2 and 5 
for reductions at year 1 were as 
follows: 
1-24%:  4% at year 2, 1% at year 5 
25-49%:  5%, 2% 
50-74%: 7%, 2% 
75-99%: 10%, 4% 
Smokers who used gum had more 
reduction at year 1 than those who 
did not (p<0.001). 
Attrition: 
Across years 2-5 194 (11%) smokers 
missed a visit. Where data were 
missing the subject was assumed to 
be smoking. 
Limitations (author):  
Reduction was not a focus 
of the Lung Health Study. 
 
Limitations (review team): 
Secondary analysis of a 
smoking cessation not a cut 
down to quit trial.   
Evidence gaps: 
Report reduction as well as 
cessation outcomes from 
cessation studies; Compare 
reduction advice versus no 
reduction advice. 
Funding sources: 
National Heart,Lung and 
Blood Institute.  National 
Institute on Drug Abuse. 
Applicable to UK? 
Quite likely - a huge 
multicentre US study. 
THR 2.3 Review 2 - Effectiveness of tobacco harm reduction approaches with the intention of quitting, with and without assistance 
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APPENDIX I – Statistical analyses (See Sections 2.6 and 4.9 for commentary) 
 
 
Figure 1 – Gradual versus abrupt reduction 
 
 
Figure 2 – Scheduled vs non scheduled reduction 
 
 
 
Study or Subgroup
1.1.1 No pharmacotherapy used
Cinciripini 1995
Gunther 1992
Marks 2002
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.35; Chi² = 7.82, df = 2 (P = 0.02); I² = 74%
Test for overall effect: Z = 0.96 (P = 0.34)
1.1.2 Pharmacotherapy available
Etter 2009
Hughes 2010
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.11; Chi² = 2.24, df = 1 (P = 0.13); I² = 55%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi² = 1.26, df = 1 (P = 0.26), I² = 20.8%
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Cinciripini 1994
Cinciripini 1995
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.43, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 2.96 (P = 0.003)
2.1.2 Without gradual reduction
Cinciripini 1995
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.97, df = 2 (P = 0.62); I² = 0%
Test for overall effect: Z = 3.26 (P = 0.001)
Test for subgroup differences: Chi² = 0.53, df = 1 (P = 0.47), I² = 0%
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17
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41.5%
100.0%
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3.15 [1.58, 6.26]
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